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Introduction: Colorectal cancer (CRC) is the third most common cancer worldwide. At 
diagnosis of CRC 20-25% of patients have metastatic disease. The liver is the most common 
metastatic site and liver metastases are detected in 25-30% of all patients. A quarter of these 
patients are amenable for liver resection that results in a five-year survival exceeding 50%. 
The indications for liver resection continue to broaden and are no longer limited by number 
and size of liver metastases nor the presence of extrahepatic metastases. Currently liver 
resection is indicated when macroscopic tumour clearance can be achieved with preservation 
of a sufficient future liver remnant. Different strategies to improve resectability exist such as 
portal vein occlusion, two-stage resections, associating liver partition and portal vein ligation 
for staged hepatectomy and thermal ablation, mainly radiofrequency ablation or microwave 
ablation (MWA). Decisions on management of patients with metastatic CRC should ideally 
be made in a multidisciplinary team (MDT) setting. Failing to do so may result in suboptimal 
management and patients that could be resected are not necessarily offered curative-intended 
treatment. As a result of this there are known regional differences in the treatment of patients 
with liver metastases that may affect survival. For patients not suitable for resection, either 
due to the metastatic burden or comorbidity omitting extensive surgery, local ablation is an 
option. 
Aims: The aim of Study I was to provide detailed population-based data of liver metastatic 
patterns, treatment and survival in patients with metastatic CRC. In Study II, the potentially 
improved resection rates were evaluated in a scenario where all patients with liver metastatic 
disease, irrespective of extrahepatic metastases, were assessed by a liver MDT. Study III 
aimed to describe the feasibility and safety of a multiple MWA strategy in patients with 
initially unresectable liver metastases. The primary aim of Study IV was to evaluate the 
accuracy and safety of antenna placement in stereotactic computed tomography-guided 
MWA of primary and secondary liver tumours. The secondary aims of Study IV were to 
evaluate the feasibility of the navigation system, to measure the procedure-related radiation 
dose and to assess the safety of high-frequency jet ventilation for target motion control. 
Patients and Methods: In Studies I and II, a population-based cohort consisting of all 
patients diagnosed with CRC in the Stockholm and Gotland region during 2008, identified 
from the Swedish Colorectal Cancer Registry, was used. Details of metastatic spread, referral 
to a MDT conference and oncologic and surgical treatment were retrieved from electronic 
patient charts and recorded during a five-year follow-up period or until death. Predictors of 
survival in Studies I and III were estimated using a Cox proportional hazards model. Survival 
curves were illustrated using Kaplan-Meier estimates and survival functions were compared 
using the log-rank test (Studies I-III). For Study II, additional information on American 
Society of Anesthesiologists grade, comorbidity and patients’ own preferences towards 
treatment, were retrieved for the 272 patients with liver metastases. Each patient was 
presented at a fictive liver MDT conference, irrespective of previous management, and 
categorized as resectable, potentially resectable or unresectable. Treatment decisions were 
compared with the original management and factors associated with referral to the liver MDT 
were assessed using logistic regression. In Study III, a multiple MWA strategy was applied to 
20 patients with initially unresectable liver metastases between October 2009 and September 
2012. The feasibility and safety of the procedure as well as local recurrence rate was 
recorded. Overall and disease-free survival in the ablated group was compared with results 
from two historic cohorts from Study I, one treated palliatively and the other resected. In 
Study IV 20 patients with primary or secondary liver malignancy, where surgical resection 
was contraindicated or the lesions were not visible on ultrasound, were included for treatment 
with percutaneous MWA using a stereotactic navigation system (Cascination AG, Bern, 
Switzerland) that shows the actual position of the tracked antenna in real time with respect to 
pre-operative CT images. Descriptive statistics were used to evaluate the accuracy of antenna 
placement, the number of antenna readjustments, safety and radiation dose. 
Results: In Study I 1026 patients with CRC were identified and liver metastases were 
detected in 272 (26.5%). Liver and lung metastases were more often diagnosed in hindgut 
(splenic flexure to rectum) compared with midgut cancer (caecum to splenic flexure) (28.4% 
versus 22.1%, p=0.029 and 19.7% versus 13.2%, p=0.010, respectively) but the extent of 
liver metastases was less for hindgut compared with midgut cancer (p=0.001). Five-year OS 
was significantly worse in liver metastatic midgut cancer compared with hindgut cancer 
(6.5% vs. 21.6%, p<0.001). In liver metastatic disease the presence of lung metastases did not 
significantly influence OS as assessed by multivariable analysis (HR 1.11, CI 0.80-1.53). At 
the fictive liver MDT in Study II, a further 22 patients (12.9%) of the 170 patients not 
previously referred to a liver MDT were considered as resectable or potentially resectable. 
Factors influencing referral to a liver MDT were age (OR 3.12, CI 1.72-5.65), ASA score 
(ASA 2 versus ASA 3, OR 0.34, CI 0.18-0.63) and number of liver metastases (OR 0.10, CI 
0.04-0.22, 1-5 versus >10 liver metastases), while male gender (OR 1.39, CI 0.84-2.30) and 
treatment at a teaching hospital (OR 1.06, CI 0.62-1.81) were not. In Study III, the ablated 
group showed a four-year overall survival of 41% compared with 70% for the historic cohort 
of resected patients and 4% for palliatively treated patients. Eighteen patients had recurrence 
in the liver, 11 had extrahepatic recurrence and 10 out of 20 treated patients were alive at a 
median follow-up of 25 months. In Study IV, the antenna was placed with a mean target error 
of 5.83.2 mm in relation to the intended target at a mean total radiation dose of 958557 
mGy x cm. 
Conclusions: Study I: Detailed population-based data on the metastatic pattern of CRC and 
survival could assist in more structured and individualized guidelines for follow-up of 
patients with CRC as well as personalized treatment, based on factors other than resectability 
as currently defined. Study II: A meaningful number of patients with liver metastases were 
not managed according to best available evidence and the potential for higher resection rates 
is considerable. Study III: The highly selected patients treated with a multiple MWA strategy 
had a survival benefit compared with patients treated with palliative chemotherapy but the 
recurrence rate was high. Study IV: Sufficient accuracy was achieved using percutaneous 
MWA with stereotactic navigation.  
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1 INTRODUCTION 
1.1 COLORECTAL CANCER 
1.1.1 Epidemiology 
Colorectal cancer (CRC) is one of the most common malignancies in Western countries. It is 
the third most common cancer in women (11.3% of all cancer) and the fourth most common 
cancer in men (10.8% of the total) in Sweden (1). There is a wide geographical variation in 
the age-standardized incidence of CRC, with a 10-fold difference between high-risk regions 
(Australia, New Zeeland, Japan and Western countries) and low-risk regions (Africa, India 
and other parts of southeast Asia) (2). CRC incidence rates have decreased over the years in 
both males and in females (3). The lifetime risk of CRC in the average person above the age 
of 50 is 5-6%, that is in a person without a personal or family history of CRC (3). In Sweden, 
4000 new cases of colon cancer are diagnosed annually and 2000 new cases of rectal cancer. 
The incidence of rectal cancer is higher in men and that of colon cancer is slightly higher in 
women (4).  
 
 
Figure 1. Tumour location of adenocarcinoma of the colon (in 
percentages), with 0.4% missing data, based on data from the National 
Cancer Registry of patients diagnosed in Sweden from 2007 to 2011 (5). 
 
 
Five-year survival has improved over the last few decades and the five-year survival for 
Swedish patients with colon and rectal cancer diagnosed between 2005-2009 was 61% for 
men, and 65% and 64% for women, respectively (6). The five-year stage-specific relative 
survival in colon cancer is presented in Table 1. Relative survival rates for rectal cancer were 
similar to colon cancer (7, 8). 
Table 1. Surveillance, Epidemiology and End Results Program data for five-year stage-specific relative survival 
rates in colon cancers based on sixth edition of the American Joint Committee on Cancer Staging Manual for 










Stage III  
B 




Colon cancer 97.1 87.5 71.5 87.7 
75.0 (T1, T2, N2) 
68.7 (T3, N1) 
47.3 (T3, N2) 
50.5 (T4, N1) 
27.1 (T4, N2) 
11 
Values are in percentages 
 2 
1.1.2 Molecular pathogenesis 
1.1.2.1 Progression from adenoma to carcinoma 
CRC is a heterogeneous disease with multiple underlying genetic mutations causing different 
clinical phenotypes. There are two main pathways involved in the progression from adenoma 
to carcinoma in the colon and rectum, namely the adenoma-carcinoma sequence and the 
serrated adenoma pathway (9), Figure 2. The former conventional pathway accounts for 
approximately 70 to 80% of all CRCs and is more prevalent in the left colon and rectum. It 
describes the gradual progression from normal mucosa to adenoma and then to carcinoma 
due to a series of genetic changes such as mutation and gene amplification. Adenomas 
typically precede cancer by over 10 years. The serrated adenoma pathway is estimated to 
account for approximately 10 to 30% of all CRCs (10, 11). Most CRCs arising in the serrated 
adenoma pathway develop from sessile serrated adenomas of the right colon and are 
notoriously difficult to recognize. This is thought to in part explain why screening 
colonoscopy is more effective in preventing left-sided cancer (12). 
 
Figure 2. The serrated adenoma and adenoma-carcinoma pathways. 
1.1.2.2 Molecular pathways in colorectal cancer progression 
Knowledge of specific genetic events that take place in colorectal carcinogenesis may have 
implications for diagnosis, prognosis and treatment. Lately, research has focused on 
interactions of hormones, energy balance, intestinal flora and inflammation to explain 
different epidemiological associations (13). There are three important molecular pathways 
leading to CRC development, either separately or in combination: 1) chromosomal instability 
(CIN), 2) microsatellite instability (MSI) and 3) CpG island methylator phenotype (CIMP). 
CIN is associated with 65-70% of sporadic CRCs and is characterized by a steadfast 
increased rate of additions and losses of chromosomal material. This pathway comprises an 
imbalance in the chromosome number, aneuploidy, and loss of heterozygosity. Responsible 
for such instability are defects in chromosomal segregation, DNA damage repair and specific 
mutations in certain oncogenes and tumour suppressor genes. The classical CIN pathway, as 
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illustrated in Figure 2, starts with the acquisition of mutations in the key tumour suppressor 
gene: adenomatous polyposis coli (APC) gene, followed by the mutational activation of 
oncogene Kirsten rat sarcoma viral oncogene homolog (KRAS) and the inactivation of the 
tumour suppressor gene TP53 (14).  
MSI occurs because of inactivating mutations in the DNA mismatch repair (MMR) genes that 
are responsible for correcting DNA replication errors (including MLH1, MSH2 and MSH6). It 
is present in 15% of sporadic CRC cases and is the distinguishing condition in Lynch 
syndrome. Based on a five-marker MSI panel, tumours with instability in >30% of markers 
are called MSI-high, those with instability in <30% are called MSI-low and those without 
microsatellite instability are called MSI stable. MSI tumours are often found in the proximal 
colon and are characterized by mucinous histology, poor differentiation and lymphatic 
infiltration (7) but confers a good prognosis (14). 
The CIMP pathway, with hypermethylation in the promoter region, results in the 
transcriptional inactivation of genes that have tumour suppressive roles or are involved in the 
cell cycle. It is referred to as an epigenetic alteration since it does not change the DNA 
sequence (14). 
1.1.2.3 Molecular markers of prognosis and therapy implications 
Mutations in the BRAF gene appear to be an early event in the CIMP tumours (serrated 
pathway), Figure 2. BRAF mutations are present in 5-10% of patients with CRC. BRAF is a 
protein kinase downstream of RAS in the RAS/RAF/MEK/ERK pathway where the last step 
controls cell cycle processes. Metastatic BRAF-mutated tumours are associated with a poor 
prognosis when compared with wild-type tumours. The clinical characteristics correlated 
with this genotype are female gender, older age, right-sided tumours, high-grade features, and 
MSI-high status (15). KRAS is mutated in 30-40% of CRC and induces cell growth by 
activation of growth factor signal transduction (7). 
Identifying biomarkers that predict sensitivity and resistance to chemotherapy is of major 
clinical importance. Differences have been identified in survival between CRC subtypes 
based on MSI, CIMP, BRAF-mutation and KRAS-mutation status. The most favourable 
survival is seen among patients with MSI-high tumours and the worst survival in tumours 
with CIMP and BRAF mutations (16). First-line treatment of CRC with 5-fluorouracil (5-FU) 
have been shown to fail in the presence of MSI tumours. Treatment with epidermal growth 
factor receptor (EGFR) inhibitors is without effect in tumours with codon 12 and 13 
mutations in KRAS, and BRAF-mutated tumours also exhibit resistance to anti-EGFR 
treatment (7). 
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1.1.3 Predisposing conditions and risk factors for colorectal cancer 
1.1.3.1 Modifiable risk and preventive factors 
Overweight and physical inactivity (17), certain types of diets (red and processed meat) (18), 
smoking (19), heavy alcohol use (20) and diabetes mellitus (21) are established risk factors 
for CRC, Table 2. The exact effects of these risk factors have been difficult to establish and 
whether they influence the risk differently depending on gender and for development of colon 
versus rectal tumours. There is emerging evidence that different infectious agents, such as 
Helicobacter pylori, are associated with an increased risk of CRC (22). Preventive factors 
established in epidemiological studies are physical activity (23), oral contraceptive use (24), 
aspirin use (25) and endoscopy with removal of pre-cancerous adenomas (26), Table 2. 
Table 2. Summary of some preventive factors and risk factors for colorectal cancer. 
Factor Relative risk 
Older age  
Family history (first-degree relative)   
Male gender  
Inflammatory bowel disease  
Diabetes  
Obesity  
Red meat  
Smoking  
Alcohol  
Helicobacter pylori () 
Oral contraceptives  
Physical activity   
Aspirin  
Colonoscopy  
Parenthesis indicates strong but not fully verified associations 
1.1.3.2  Insusceptible risk factors 
The single most important risk factor is advanced age and CRC is predominantly a disease of 
late middle-aged and elderly individuals (27). It is estimated that up to 20% of CRC cases 
have a familial component but without a clear hereditary disease (28). Individuals with a 
family history of CRC and colorectal adenoma in a first-degree relative are at increased risk 
of developing CRC compared with those without such a history. Relative risks are greatest 
for relatives of patients diagnosed young, (relative risk 3.87) and those with more than one 
relative with CRC (relative risk 4.25) (29). There is an increased risk of CRC in patients with 
inflammatory bowel disease but the risk is declining compared with historic cohorts. 
Hereditary CRC of a syndrome type account for nearly 6% of all cases (7). 
  5 
1.1.4 Classification of colorectal cancer 
Most CRCs are adenocarcinomas (75-80%) followed by mucinous adenocarcinoma (10%) 
and serrated adenocarcinoma (10%). Tumour grading into high-grade and low-grade is based 
on the proportion of tumour composed of glands relative to solid areas. The most important 
predictive factor of tumour behaviour and outcome is the anatomic extent of tumour spread, 
classified according to the TNM staging system. The TNM classification is divided into three 
parameters where T describes the primary tumour (Figure 3), N the nodal (lymph node) 
status and M the presence or not of distant metastases (30), Table 3 and 4. Other prognostic 
factors are carcinoembryonic antigen (CEA), tumour deposits, perineural invasion, MSI, 
tumour regression grade, vessel invasion and extramural vessel invasion (6). 
Table 3 (left). TNM-Classification 7th edition for colorectal cancer according to local invasion depth (T-status), 
lymph node (LN) involvement (N status), and presence of distant metastases (M status). Table 4 (upper right). 
Classification of colorectal cancers according to Union Internationale Contre le Cancer stage (UICC stage) (30). 
Figure 3 (bottom right). Illustration of tumour invasion depth. T1 tumours are sub-classified into sm1, sm2, and 
sm3, invading the superficial, middle and deep one-thirds of the submucosa, respectively. 
1.1.5 Treatment of colorectal cancer 
1.1.5.1 Surgical treatment 
Radical excision of a colon tumour along with the appropriate vascular pedicle and 
accompanying lymphatic drainage is the appropriate surgical strategy. Total mesorectal 
 Definition 
Primary tumour (T) 
Tx Primary tumour cannot be assessed 
Tis Carcinoma in situ: intraepithelial or 
invasion of lamina propria 
T1 Tumour invades submucosa 
T2 Tumour invades muscularis propria 
T3 Tumour invades through the muscularis 
propria into pericolorectal tissues 
T4a Tumour penetrates to the surface of the 
visceral peritoneum 
T4b Tumour directly invades or is adherent to 
other organs or structures 
Regional Lymph Nodes (N) 
Nx Regional LN cannot be assessed 
N0 No regional LN metastasis 
N1a Metastasis in one regional LN 
N1b Metastasis in 2-3 regional LN 
N1c Tumour deposit(s) in the subserosa, 
mesentery, or non-peritonealized pericolic 
or perirectal tissues without regional LN 
N2a Metastasis in 4-6 regional LN 
N2b Metastasis in seven or more regional LN 
Distant metastases (M) 
M0 No distant metastasis 
M1a Metastases confined to one organ or site 
M1b Metastases in more than one organ or 
peritoneum 
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excision is the optimal surgical treatment for low or mid-rectal cancer (31). Surgical resection 
is undertaken in all patients unless the tumour is deemed locally unresectable, if there is a 
medical contraindication to surgery or in patients with asymptomatic primary tumours in the 
presence of incurable disseminated disease. 
1.1.5.2 Chemotherapy 
For decades, fluoropyrimidines have been the mainstay of CRC chemotherapy (intravenous 
5-FU plus leucovorin [LV] or oral capecitabine [Xeloda]). Since the turn of the century, two 
new cytotoxic agents have been introduced: a topoisomerase inhibitor named irinotecan 
(Campto) and oxaliplatin (Eloxatin), a third-generation platinum compound (32). Adjuvant 
treatment for six months after radical excision of colon cancer reduces the risk of relapse and 
enhances the chance for long-term survival. In stage III disease, there is a strong evidence 
base that supports adjuvant chemotherapy (6). A number of risk factors are taken into account 
in patient selection for adjuvant chemotherapy in stage II colon cancer. Factors that increase 
the risk of relapse include T4 disease, the presence of vessel invasion, <10 examined lymph 
nodes, poorly differentiated tumours and emergency surgery. Individuals with MSI-high are 
at lower risk of relapse, at least in stage II disease. The NSABP C07 study demonstrated that 
the addition of oxaliplatin to infusional 5-FU/LV resulted in a better five-year disease-free 
survival (DFS) (33). The MOSAIC trial stated that the absolute improvement in OS for high-
risk stage II disease was 1.7% as opposed to 0.1% in low-risk stage II and 4.2% for stage III 
(34). In summary, adjuvant treatment with 5-FU/leucovorin reduced the relative risk for 
relapse in stage III disease with 30-40%. When adding oxaliplatin, the relative risk reduction 
is further increased by 19%. In stage II disease, the relative risk reduction is 20 % with 5-
FU/LV and an additional 18% with oxaliplatin (6). 
1.1.5.3 Targeted therapy 
Cetuximab (Erbitux) and panitumumab (Vectibix) are anti-EGFR antibodies that inhibit 
downstream signalling of cell growth and proliferation and apoptotic pathways. In patients 
with KRAS mutations, the mutations cause constitutive activation of signalling cascades 
downstream to EGFR and therefore anti-EGFR therapy is not effective (35). Anti-EGFR 
treatment has shown clinical benefit only in tumours that are KRAS wild-type. Bevacizumab 
(Avastin), an anti-vascular endothelial growth factor antibody that inhibits soluble protein 
and results in an anti-angiogenic effect in tumours, is used as a first line therapy in metastatic 
CRC (36). The combinations of biologic and cytotoxic agents have become the standard of 
care for the treatment of metastatic CRC but lack proven benefits as adjuvant treatment of 
primary colon cancer. Two randomized trials, the NSABP C08 and the NO147 trials, 
assigned patients to FOLFOX with or without bevacizumab and cetuximab, respectively. 
Both failed to prove significant differences in DFS (37, 38). 
1.1.5.4 Radiotherapy 
Radiotherapy uses ionising radiation to eliminate cancer cells. The indications for radiation in 
rectal cancer are to reduce the risk of local recurrence and to shrink locally advanced tumours 
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to facilitate successful resection. In a Cochrane review it was concluded that pre-operative 
radiotherapy reduces the risk of local recurrence compared with surgery alone and overall 
mortality is marginally improved (39). The addition of 5-FU/LV to pre-operative long-course 
radiotherapy halved the risk of local recurrence but had no impact on overall survival (OS) in 
two large European phase III trials (40, 41). 
1.1.6 Differences between right- and left-sided colon cancer  
1.1.6.1 Incidence, survival and clinical presentation 
An increasing incidence of right-sided colon cancer has been seen over the last decades. 
Patients with right-sided tumours are more often females, are slightly older and more 
often present with advanced (T3/T4) tumours (42). Data from a meta-analysis 
demonstrated that those with right-sided cancer had a significantly worse prognosis in 
terms of OS than those with left-sided cancer (43). Patients with right-sided tumours often 
present with more subtle signs such as microcytic anaemia and weight loss while left-sided 
typically present with rectal bleeding and alterations in bowel habits (43). 
1.1.6.2 Embryology and anatomy 
The proximal and distal colon segments are of different embryologic origin.  The caecum, 
ascending colon and proximal two-thirds of the transverse colon originate from the 
midgut while the remaining segments to the upper anal canal derive from the hindgut. 
Branches of the superior mesenteric artery supply the proximal colon, while the distal 
colon gets its blood supply from the inferior mesenteric artery (44). Nearly all venous 
blood from the colon flows into the portal vein and the liver capillaries are the first 
capillaries encountered by portal blood-borne cancer cells. A portion of venous blood 
from the rectum enters the inferior vena cava (IVC) and thus directly reaches the lungs 
without a liver pass (45). 
1.1.6.3 Immunological and molecular differences 
There is an increased immune activity in the caecum compared with the rectum and the distal 
colon and rectum have the highest concentration of microbiota (44). Tumours with CIN are 
more often found in the hindgut and tumours in the right colon are more often 
CIMP/MSI/BRAF positive (44). 
1.1.6.4 Response to chemotherapy 
Right- and left-sided cancers benefit equally from adjuvant FOLFIRI chemotherapy. The 
benefit gained from adjuvant FOLFOX is superior for left-sided cancers. Cetuximab 
treatment in KRAS wild-type cancers is inferior for right-sided cancers in terms of PFS (46). 




1.2 LIVER METASTATIC COLORECTAL CANCER 
1.2.1 Epidemiology 
The incidence of liver metastases ranges between 23.6 and 27.3% in population-based studies 
(48-51). At diagnosis of CRC, 20-25% of patients have metastatic disease (52), in which liver 
metastases are present in 14.5-17.7% of patients (50, 51). The incidence of detection of 
metastases at the time of diagnosis of the primary tumour is rising, probably due to better 
imaging practices and improved imaging techniques (53). Five- and 10-year cumulative 
incidences of metachronous metastases are reported to be 14.5-15.1% and 16.9%, 
respectively (50, 51). Around 85% of liver metastases are diagnosed within one year, 94% 
within two years and 97.5% within the first three years after diagnosis of the primary CRC 
(50). Among patients with no recurrence five years after diagnosis, 2.2% developed liver 
metastases between five and 10 years (54). The incidence of metachronous liver metastases 
with respect to TNM stage is 3.7% for stage I tumours, 13.3% for stage II and 30.4% for 
stage III (51). There is no consensus on the definition of synchronous versus metachronous as 
used in the context of CRCLM, which might explain some of the differences in incidence. 
The time-point of diagnosis of the primary tumour, the time of operation of the primary 
tumour and a variation of time intervals related to these time-points have been used. The 
definition of synchronous detection most commonly used today is the detection of liver 
metastases either before or during the surgical procedure for the primary tumour (55). Data 
from Manfredi et al. showed that five-year survival rates were inferior in synchronous liver 
metastases compared with metachronous detection (3.3% vs. 6.1%), while other studies have 
reported no significant difference (51). Patients who present with synchronous liver 
metastases tend to have a more locally advanced primary tumour and present with a greater 
metastatic burden compared with those who develop metachronous metastases (56). 
Liver metastases are more often diagnosed in men, a fact that remains significant after 
adjustment for age and is thought to be explained by both an actual higher frequency of liver 
metastases as well as a higher incidence of CRC among men (51, 54). Past studies have 
reported a higher proportion of liver metastases among younger patients and a tendency to a 
more advanced TNM stage and significantly longer interval between symptom onset and 
diagnosis of the primary tumour compared with older patients (51, 57). 
Conflicting results exist on whether the site of CRC influences the frequency of liver 
metastases. In a German study as well as a United States-based study, colon cancer more 
often caused haematogenous spread to the liver (56, 58). In another study by Lee et al. the 
extrahepatic recurrence rate was higher in patients with lower rectum cancer, although there 
was no difference between the hepatic recurrence rates (59). In a Norwegian study, left-sided 
colon cancer was found to be associated with an increased risk of metastatic spread to the 
liver (60). 
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1.2.2 Liver metastatic process and growth pattern 
Stephen Paget first described the “seed and soil” hypothesis in 1889 in which the metastatic 
“seed” preferentially grows in an organ environment that provides a suitable “soil”. More 
recently, the hypothesis has expanded to the concept of “pre-metastatic niche formation”. 
Cellular and molecular changes are thought to occur in target tissue well before tumour cells 
leave the primary site, rendering the target site susceptible to metastatic cells (61). 
The liver metastatic process can be divided into a series of stages (62-64). First, the cancer 
cells need to “escape from the primary tumour”. The new blood vessels developing in the 
primary tumour during growth, angiogenesis, provide an escape route whereby tumour cells 
can enter into the vascular system (intravasation), which is the second step. Tumour cells 
might also enter the blood circulation system indirectly via the lymphatic system. As a third 
step, the tumour cells need to “survive in the circulation”. Once in the circulation, CRC cells 
bind to and cover themselves with platelets leading to better protection from shear stress and 
the immune response (65). Circulating metastatic cells can enter the liver via the portal vein 
or the hepatic artery. “Avoidance of host defence mechanisms” is the fourth step. In the liver 
sinusoids, different cells with anti-tumour activity meet the circulating tumour cells. Kupffer 
cells are specialized macrophages lining the walls of the sinusoids and Pit cells are large 
granular lymphocytes with high cytotoxic activity against tumour cells (65). If the cancer 
cells survive so far, the fifth step is the “arrest at a new site”. Controversy exists over 
whether mechanical trappings alone in the sinusoidal vessels or specific interactions with the 
endothelium are required for the formation of metastases. This is followed by “extravasation 
into the tissue”. Once the tumour cells have reached the new site, the cells must initiate and 
maintain “growth” to first form pre-angiogenic micrometastases and finally macroscopic 
metastases. 
1.2.3 Imaging of liver metastases 
Contrast-enhanced computed tomography (CT) scans are routinely used for primary staging 
and disease surveillance of CRC. The recommended follow-up routines on resected patients 
in Sweden include, besides CEA, CT chest and abdomen at 12 and 36 months post-
operatively (6). 
Contrast-enhanced ultrasound (US) is significantly inferior to contrast-enhanced CT for the 
pre-operative detection of liver metastases (66). The best methods for detection of liver 
metastases are CT and magnetic resonance imaging (MRI) (67). Superior diagnostic 
performance with increased accuracy and detection of additional liver metastases are 
achieved when gadoxetic acid-enhanced MRI (Gd-EOB-DTPA-MRI) is used (68, 69). The 
combination of diffusion-weighted (DW)-MRI and Gd-EOB-DTPA-MRI has the highest 
sensitivity for detecting liver metastases on a per-lesion basis (70). 
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1.2.4 The importance of a liver-specific multidisciplinary team assessment 
Ideally, the management and treatment of patients with liver metastases should take place in a 
specialist hepato-pancreato-biliary centre or as part of a network with established referral 
routines to a specialist centre. The importance of discussing patients with liver metastatic 
disease at a specialist hepatobiliary multidisciplinary team (MDT) meeting has been 
demonstrated in several observational studies (71, 72). To qualify as a liver MDT, a 
hepatobiliary surgeon and an oncologist and a radiologist specialised in liver should 
participate. Since the use of ablative treatment is increasing, an interventional radiologist or 
surgeon should also be present (73). Discussion at a liver MDT is associated with higher 
resection rates (74) and improved DFS (75) and OS (72, 76). Unfortunately, patients that may 
benefit from resection are not always properly referred (71). There are known discrepancies 
between medical oncologists and surgeons in assessing resectability and indications for pre-
operative chemotherapy (77-79). Some physicians and medical oncologists still judge 
bilateral disease and large tumour size as contraindications for surgery (80). A difference in 
referral rates between hospitals in the same region has been reported (74, 81), with data 
suggesting that a lower referral rate is followed by a lower resection rate and, consequently, a 
lower survival rate than could ultimately be achieved (48, 74, 81). Moreover, practice 
patterns related to defining resectable CRCLM and the utilization of curative therapy vary 
significantly between hospitals (82, 83). 
1.2.5 Prognostic factors in colorectal cancer liver metastases 
In 1999, Fong and colleagues proposed a clinical risk score for predicting recurrence after 
hepatic resection for CRCLM based on five clinical criteria: nodal status of the primary 
tumour, disease-free interval from the diagnosis of the primary tumour to the discovery of the 
liver metastases of <12 months, number of tumours >1, pre-operative CEA level >200 ng/ml, 
and the size of the largest tumour >5cm (84). Major improvements in surgical technique and 
perioperative management of the patient, as well as the introduction of modern chemotherapy 
have potentially made the scoring system out-dated. A more simplified scoring system for 
disease-specific survival and recurrence after R0 resection was proposed by Settmacher in 
2011. Patients with an extrahepatic tumour at the time of liver surgery are considered as high 
risk, as are patients with one of the two following factors: N2 of primary tumour or more than 
two liver metastases (85). All other patients are regarded as low risk. The number of liver 
metastases is one of the most used predictive factors and the cut-off for considering the 
patient to have a worse prognosis varies between >1 and >7 lesions. The size of the largest 
metastasis is also frequently used as a prognostic marker with the cut-off usually being set at 
5 cm. The presence of extrahepatic disease is regarded as a factor associated with worse 
survival and has up until recently been considered as a contraindication to surgery (73). RAS 
mutations (KRAS and NRAS) have been shown to be independent predictors of poor OS and 
DFS as well as being associated with a higher recurrence risk in patients undergoing surgery 
for CRCLM (86). 
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Progression on systemic therapy is considered a poor prognostic factor that could exclude a 
patient from curative-intended liver resection. In patients with potentially resectable 
metastases, the goal has often been to achieve a high response rate as assessed by the 
RECIST (response evaluation criteria in solid tumours) criteria in order to convert 
unresectable metastases to technically resectable metastases (87). Since the introduction of 
biologic agents that mainly have a cytostatic effect, the relevance of the RECIST criteria has 
been questioned and the addition of non-sized based morphologic response criteria has been 
proposed (88, 89). Several studies have described both weak associations between RECIST 
and pathologic response to chemotherapy and the absence of associations between RECIST 
response and long-term outcomes (90, 91). 
1.3 TREATMENT OF COLORECTAL LIVER METASTASES 
1.3.1 Liver anatomy and function 
The liver is the largest solid organ in the human body and has a unique dual blood supply. 
Twenty-five percent of the supply originates from the hepatic artery and 75% from the portal 
vein. Oxygen-rich blood from the hepatic artery and the nutrient-rich blood from the portal 
vein is mixed in the hepatic sinusoids before leaving the liver through the hepatic veins that 
ultimately coalesce into three hepatic veins that drain into the inferior vena cava (IVC) (92). 
The liver performs several essential tasks including ammonia detoxification, urea synthesis, 
protein synthesis and breakdown, bile synthesis and secretion, gluconeogenesis and 
detoxification of drugs, bacteria and bacterial toxins. For most functions the capacity of the 










The classification of liver anatomy according to Couinaud divides the liver into eight 
functionally independent segments, each with its own blood supply and biliary and venous 
drainage (93), Figure 4. The right and left hemi-livers are separated by the middle hepatic 
vein in a plane running from the IVC to the gallbladder fossa (Cantlie’s line). The right hemi-
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liver is divided into anterior (segments V and VIII) and posterior (segments VI and VII) 
sections by the right hepatic vein (94). The falciform ligament/ligament teres and the 
umbilical fissure serve as landmarks of the division of the left hemi-liver into a medial 
section (segment IV, subdivided in segments IVa and IVb) and a lateral section (segments II 
and III). The plane between these two sections is occupied by the vertical portion of the left 
portal vein. The plane between the superior and inferior segments is approximately on the 
level of the portal bifurcation (92), as illustrated in Figure 4. 
The remarkable capacity of the liver to regenerate makes resections of up to 75% of the liver 
parenchyma feasible. The future liver remnant (FLR) would then be sufficient for 
maintenance of post-operative function and regeneration on condition that there is no 
underlying liver dysfunction. Within 6-8 weeks following major resection, the liver will 
regain its original volume. Three key factors coexist that facilitate liver regeneration, namely 
the ability of differentiated hepatocytes to proliferate, the inhibition of processes connecting 
injury to programmed cell death and alterations in the microenvironment of the liver cells 
supporting growth (31). If cirrhosis, fibrosis or ongoing liver injury such as biliary 
obstruction or sepsis is present, liver regeneration might be impaired. Chemotherapy-
associated liver changes mainly occur in patients treated with oxaliplatin or irinotecan. The 
influence of the sinusoidal obstruction syndrome (“blue liver”) caused by oxaliplatin-based 
chemotherapy on outcome after liver resection was reviewed in a recent meta-analysis. It 
showed no significant effect on short-term outcome (95). Chemotherapy-associated 
steatohepatitis related to irinotecan treatment, especially in obese patients, has been shown to 
increase morbidity and 90-day mortality after resection (96). Estimating the function of the 
FLR has proven difficult since there is a poor correlation between volume and function, 
especially in diseased livers (97). Peri- and intraoperative conditions such as prior 
chemotherapy, pre-existing steatosis, oxidative stress and ischaemia/reperfusion injury, most 
likely compromise function of the FLR. 
1.3.2 Liver resection rate trends over time 
The number of patients amenable for resection of CRCLM has increased dramatically over 
recent years due to expanding indications, major surgical and oncological advances and the 
concept of multimodality treatment (73). The majority of publications addressing treatment of 
CRCLM come from high volume centres and may not be representative of practice in 
general. In a Swedish population-based study, Sjövall et al. reported a resection rate of 4% 
among all patients with detected liver metastases during the time period of 1996-2001 (48). 
Similarly, Cummings et al. published a resection rate of 6.1% between 1991-2001 (98). The 
proportion of patients who had surgical resection was higher in a French study by Leporrier et 
al.: 17.3% between 1994-2002 (49). The resection rate has continued to increase and in a 
recent study on surgical management among patients with CRCLM, 26.2% of patients 
underwent resection (2002-2012) (50). 
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1.3.3 Factors influencing surgical resection rate 
Patients with CRC and a high socioeconomic status have more favourable surgical treatment 
characteristics than patients with a low socioeconomic status (99). Socioeconomic status also 
influences the likelihood of liver resection, where the socioeconomically favoured population 
are resected to a greater extent (100). In a large population-based series on surgical 
management and outcomes of patients with CRCLM, women, older patients and those who 
resided in the most socioeconomically deprived areas were significantly less likely to 
undergo surgical resection (101). In two Swedish nationwide studies, inequalities in surgical 
resection rates were demonstrated where married patients were more likely to have their liver 
metastases resected. It was also found that for female patients with rectal cancer civil status, 
education and level of income were all more important than age in the selection for liver 
surgery (102). In the second study on patients with synchronously detected liver metastases, 
females and patients treated outside of university hospitals were less likely to undergo liver 
resection (103). Other known factors associated with a lower probability to undergo a hepatic 
resection are old age, co-morbid disease, a high number of liver metastases, synchronous 
liver metastases and the presence of extrahepatic disease (101, 103). 
1.3.4 Criteria for surgical resection and long-term survival 
Historically, the prognosis of patients with CRCLM not treated with either chemotherapy or 
surgery was exceptionally poor, with a median survival of 5-10 months. Surgical resection of 
CRCLM is a potentially curative treatment with currently reported five-year survival rates of 
20-58% (54, 87, 104-107) and 10-year survival rates of 22-23% (84, 104, 108). In data 
published from single large academic institutions five-year survival rates of 64% are reached 
(109). In population-based materials, 10-year OS range from 4.6 to 15.1% depending on 
number of liver metastases and surgical resection (50). Ten-year relative survival rates as 
high as 34% have been reported (54). An actual 10-year cure rate is documented in one of six 
resected patients (110). When evaluating patients for surgery, both oncological and technical 
operative factors should be considered. Current technical contraindications to liver resection 
include the inability to achieve a R0 resection with >25-30% FLR and the presence of 
unresectable extrahepatic disease, as outlined in Table 5 (73, 111, 112). 






Adapted from Adam et al. (111). Patients should be categorised as A1 or A2/B1, B2 or B3. 
Category Contraindication 
Technical (A)  
1) Absolute 
Impossibility of R0 resection with >30% liver remnant.  
Presence of unresectable extrahepatic metastases. 
2) Relative 
R0 resection possible only with complex procedure. 
R1 resection 
Oncological (B)  
1 Concomitant extrahepatic disease (unresectable) 
2 Number of lesions >5 
3 Tumour progression 
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Potential cure can be achieved in a fraction of patients after R1 liver resection (113). In the 
era of modern chemotherapy regimens, tumour biology is speculated to be a more important 
factor in survival than surgical margin, suggesting that the risk of an R1 resection should not 
be considered as a contraindication to surgery (114, 115).  
Extrahepatic disease is not an absolute contraindication to resection with five and 10-year OS 
of 28% and 10%, respectively. Liver resection, when complete resection of extrahepatic 
disease is possible, has proven safe and long-term survival can be achieved in spite of disease 
recurrence in the majority of patients and a true cure is rare (116-119). 
A large number of liver metastases should not be a contraindication to curative-intended 
treatment as resection of multiple bilateral liver metastases as well as multiple thermal 
ablation of initially unresectable metastases have demonstrated a survival benefit (109). Also, 
age is not a contraindication even though long-term outcomes are inferior compared with 
younger patients. Nevertheless, in a substantial proportion of elderly patients, long-term 
survival will be achieved (120, 121). 
The presence of resectable lung metastases is neither a poor prognostic factor nor a 
contraindication to resection of liver metastases and similar OS is reported for patients who 
underwent resection of liver and lung metastases and those who had undergone removal of 
isolated liver metastases leaving the lung metastases in situ (122, 123). 
1.3.5 Resectable liver metastases 
As illustrated in Figure 5, both surgery upfront and perioperative chemotherapy are options 
in patients presenting with technically resectable liver metastases and favourable oncological 
criteria. No clear recommendation exists since the EPOC study on perioperative 
chemotherapy failed to show a major advantage in five-year OS in the group treated with 
perioperative chemotherapy versus surgery-only, 51% versus 48%, respectively (124). 
However, based on the same trial, if adverse prognostic factors are present, perioperative 
chemotherapy is recommended with three months pre-operative FOLFOX (or capecitabine 
with oxaliplatin) and three months postoperative chemotherapy using the same regime. This 
has shown to result in an 8% increase in PFS after three years. The New EPOC trial that 
investigated the possible benefit of 
adding anti-EGFR treatment to FOLFOX 
in the neo-adjuvant setting showed a 
shorter PFS for combination therapy and 
this combination is not to be used in this 
setting (125).  
Figure 5. Categorization of patients according to 
technical and oncological criteria. FOLFOX 
infusional 5-fluorouracil, leucovorin, oxaliplatin. 
(Reproduce from Van Cutsem et al. (73)) 
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An increased surgical morbidity with neo-adjuvant treatment was demonstrated in both 
studies. In patients with more unfavourable prognostic factors, no evidence for best treatment 
strategy exists, and FOLFOX or a chemotherapy doublet plus monoclonal antibody therapy 
can be considered (73). Figure 5 illustrates the proposed categorization of patients into 




Figure 6. Case illustration 1.  
64-year old woman with resected colon cancer who presented 
with synchronous liver metastases and underwent right 
hemihepatectomy and surgery of the primary. Six months later, 
an additional liver metastasis was detected between segments 
two and three, superficially, measuring 3 cm. Repeated 
resection was completed and the patient is recurrence free at 
one-year follow up.  
 
1.3.5.1 Recurrence after liver resection 
The recurrence rate following curative-intended surgery is reported to be 56.7-63% within 
two years (85), and 93% of recurrences are found to occur within the first five years of 
follow-up (108). The first unique site of recurrence is the liver (45%), followed by lung 
metastases (18%), liver and extrahepatic metastases (14%), other metastases (14%), and loco-
regional recurrence only (9%) (85). Time to recurrence in the liver is correlated with 
synchronous detection, the number of lesions, R status and American Society of 
Anaesthesiologists (ASA) score (126). If recurrence occurs after curative resection of liver 
metastases, repeat hepatectomy for additional liver metastases should be considered and 
results in survival benefit equal to that of a first resection (127). 
1.3.6 Potentially resectable liver metastases 
Conversion therapy is given to patients with potentially resectable liver metastases with the 
aim to transfer technically unresectable liver metastases into a resectable state. In patients 
with initially unresectable disease, chemotherapy can convert up to 20% of patients to 
resectability (73, 128). Survival is slightly impaired in the patient category undergoing 
conversion therapy followed by surgery compared to initially resectable disease but it is still 
considerably better than if resection is not to be carried out (129). It also seems as if 
converted patients suffer from earlier liver recurrence (130). Significant increased resection 
rates were seen in the CRYSTAL and OPUS trials after treatment with FOLFIRI and 
FOLFOX, respectively, combined with cetuximab (131, 132). Patients with technically 
unresectable and/or >5 liver metastases were included in the CELIM trial and treated with 
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either FOLFOX plus cetiximab or FOLFIRI with cetuximab. Encouraging resection rates of 
40-43% were achieved across the two treatment arms (133). This was followed by the 
European phase II OLIVIA trial, where patients with unresectable liver metastases were 
randomised to an intense arm, FOLFOXIRI plus bevacizumab or a conventional arm, 
FOLFOX plus bevacizumab. The intense arm was associated with both higher response and 
resection rates (134). In a systematic review of patients with initially unresectable liver 
metastases who underwent systemic chemotherapy, 22.5% had a curative resection and a 
median survival time of 45 months (135). A nomogram to predict survival after hepatectomy 
in patients with initially unresectable liver metastases who underwent conversion therapy was 
recently presented by Adam and colleagues. Five independent prognostic factors for survival 
were identified, namely node-positive primary, tumour number at hepatectomy > 6, 
carbohydrate antigen 19-9 level at hepatectomy > 37 units/ml, disease progression during 
first-line chemotherapy and presence of concomitant extraheptic disease (136). 
In patients in need of tumour shrinkage, molecular profiling is essential in determining 
further treatment, Figure 7. After the administration of conversion therapy, an evaluation of 







Figure 7. Treatment algorithm for tumours in need of shrinkage and conversion to resectable disease. Wild-type 
(wt). Mutation (mt). Chemotherapy (CT). 
1.3.7 Surgical strategies to improve resectability 
1.3.7.1 Portal vein occlusion 
Portal vein embolization (PVE) or portal vein ligation (PVL) induces atrophy of the liver to 
be resected and hypertrophy of the liver that will constitute the FLR and is used in patients 
with a marginal FLR to prevent post-resection liver failure and death. In a meta-analysis of 
articles on the impact of PVE on liver resection, 85% of patients underwent the intended 
hepatectomy after PVE (137). In performing PVE, the portal vein can be accessed either by a 
percutaneous transhepatic approach, that is most commonly used, or via the ileocolic vessels. 
In a meta-analysis results of PVE and PVL were comparable in terms of percentage increases 
in the FLR, morbidity and mortality (138). 
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1.3.7.2 Two-stage hepatectomy 
A lesser resection of metastases in the FLR and PVE or PVL during surgery is followed by 
the major hepatectomy when volume manipulation has resulted in a sufficient FLR. In 
patients with bilateral disease, an alternative is a single-stage procedure with a combination of 
local ablation that results in survival rates similar to two-stage hepatectomy but with less 
overall morbidity (139). 
1.3.7.3 Associating liver partition and portal vein ligation for staged hepatectomy  
Sufficient FLR hyperthrophy after portal vein occlusion is not always achieved. There is 
furthermore the risk of tumour progression during the 3-5 week waiting period that may 
preclude further surgery (140). Associating liver partition and portal vein ligation for staged 
hepatectomy (ALPPS) was first published by Schnitzbauer et al. in 2012 (141). Briefly, at a 
first operation the liver parenchyma is transected in the intended resection plane and PVL of 
the liver to be resected is performed. During the initial procedure, any tumours in the FLR 
can be removed by resection or ablation. Once sufficient hyperthrophy of the FLR is 
achieved, the deportalized liver is resected at a second operation (142). It is recommended 
that the CT for volumetry after step one should be done 8-10 days after the first operation and 
repeated weekly for four weeks if the FLR is insufficient (143). The rapid regeneration 
achieved with the ALPPS procedure is probably multifactorial, including redistribution of 
portal blood by the PVL, interruption of intrahepatic portal collaterals with parenchyma 
transection and induction of an inflammatory response with the release of growth factors. Part 
of the previous paradigm for liver surgery, namely that the FLR must consist of two 
continuous segments, was challenged by the introduction of monosegment ALPPS, basing 
the FLR on only one Couinaud segment (144). ALPPS has been demonstrated to offer a 
higher rate of complete resection in patients with primarily unresectable liver tumours 
compared with conventional staged hepatectomies but with a higher mortality (145). A meta-
analysis published in 2015 with data from 295 patients revealed a 90-day mortality of 11% 
and Clavien-Dindo complication grade IIIa or higher occurred in 44% of patients (146). 
Proper oncological results of this procedure are lacking. Intermediate oncological results 
were investigated by Björnsson and colleagues and the estimated two-year OS was 59% from 
surgery and 73% from diagnosis of liver metastases. In a subsequent study, the OS, rate of 
severe complications and perioperative mortality were comparable with two-stage 
hepatectomy (147). 
1.3.7.4 Ablative treatment 
For patients with metastases unfavourably positioned for resection or with a large number of 
metastases, ablative treatment can be used in combination with systemic therapy and 
resection, Figure 8. 
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1.3.7.5 Thermal ablation 
Thermal ablation such as radiofrequency ablation (RFA) and microwave ablation (MWA) has 
been used for some years with data supporting its safety and efficacy. This is elaborated on in 
chapter 1.5. The CLOCC trial was the first randomized study on the efficacy of RFA in 
unresectable liver metastases. Difficulties in patient recruitment resulted in premature closure 
of the trial with the result that the study did not achieve sufficient power to demonstrate a 
significant result for its primary end-point of OS. In fact, there was no difference in 30-month 
OS between RFA plus chemotherapy versus chemotherapy alone (61.7% versus 57.6%, 
respectively) but a significantly improved three-year PFS was seen (27.6% versus 10.7%, 
respectively) (148). 
 
Figure 8. Flow-chart of different ablative treatment modalities for CRCLM. High-dose-rate (HDR)-
brachytherapy. Stereotactic body radiation therapy (SBRT). Irreversible electroporation (IRE). Selective internal 
radiation therapy (SIRT). Transarterial chemoembolization (TACE). High-intensity focused ultrasound (HIFU). 
1.3.7.6 High-dose-rate brachytherapy 
High-dose-rate brachytherapy does not have the limitations inherent to thermal ablation 
techniques. However, CRC tumour cells seem less sensitive to radiation compared with 
hepatocellular carcinoma (HCC) cells, hence the technique is not as commonly used in the 
multimodality treatment of liver metastases. One or multiple co-axial catheters are inserted 
using image-guidance, followed by treatment planning and single fractionated high dose 
irradiation (149). 
1.3.7.7 Stereotactic body radiation therapy  
Stereotactic body radiation therapy (SBRT) is defined as a method of external beam 
irradiation (photons or particles) that accurately delivers a high dose of irradiation in one or 
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few fractions to an extracranial target. SBRT has been reported to achieve high local control 
rates, similar to that of RFA in unresectable oligometastatic disease (150). 
1.3.7.8 Irreversible electroporation 
Irreversible electroporation (IRE) is increasingly used in patients with tumours close to the 
portal triad or large vessels where thermal ablation is considered less effective and potentially 
harmful. High-voltage electrical pulses are delivered through precisely placed parallel 
electrodes causing innumerable permanent nanopores in the cell membrane that disrupt 
cellular homeostasis and cell death follows (151). The capability of IRE to preserve vital 
structures, such as arteries, veins and intrahepatic bile ducts, is explained by the fact that cell 
death is mediated by apoptosis through disruption of the cell membrane and since vascular 
elastic and collagenous structures are mainly formed by proteins, such structures are not 
damaged by IRE ablation (152). Published local control rates are inferior to thermal ablation, 
ranging from 55-93% with a median follow-up below one year (153-155). 
1.3.7.9 Selective internal radiation therapy 
Selective internal radiation therapy (SIRT), also called radioembolization, is used as salvage 
therapy for patients with unresectable liver metastases. Microspheres containing yttrium-90 
are permanently implanted into the liver tumour via the hepatic artery. Radiation is delivered 
within a small range from the microsphere (2.5 mm) and therefore spares adjacent normal 
liver tissue (156). A review of the role of SIRT concluded that there is no evidence that SIRT 
improves survival or quality of life in CRCLM (157). SIRFLOX was a randomized trial 
investigating the efficacy of adding SIRT to FOLFOX-based first-line chemotherapy in 
patients with liver-dominant or liver-only metastases. The addition of SIRT did not improve 
PFS but delayed disease progression in the liver (158). 
1.3.7.10 Transarterial chemoembolization 
In transarterial chemoembolization (TACE), one or more chemotherapeutic drugs and 
embolic materials are injected into the hepatic artery. The method is most suitable for 
hypervascular tumours. A strong cytotoxic and ischaemic effect is achieved after the intra-
arterial infusion of a cytotoxic agent followed by embolization of the tumour-feeding blood 
vessels. The embolic material reduces the blood flow and prolongs tumour exposure to the 
chemotherapeutic agents. In a propensity score matching study, no significant differences in 
OS were seen in patients with unresectable liver metastases treated with or without TACE 
(159).  
1.3.7.11 Hepatic arterial infusion 
With hepatic arterial infusion (HAI) therapy, chemotherapy is delivered through the hepatic 
artery and is based on the principle that CRCLM are mainly supplied by arterial 
neovascularization via the hepatic artery, whereas healthy liver parenchyma is supplied by a 
mixture of 25% arterial and 75% portal blood. The administration of drugs with a high first-
pass effect that rapidly metabolize in the liver allows for a high concentration of active drug 
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in the liver. In patients with liver metastases refractory to standard chemotherapy, a response 
to HAI resulting in anti-tumour activity with conversion to resectability and improvement in 
survival can be achieved (160, 161). 
1.3.7.12 High-intensity focused ultrasound 
High-intensity focused ultrasound (HIFU) is emerging as a minimally invasive treatment 
option for patients with HCC and CRCLM. It can be used both for thermal (coagulative 
necrosis) and mechanical destruction (subcellular fragmentation) of tissue. It uses acoustic 
lenses or curved piezoelectric transducers to focus beams of US on a target located deep in 
the body. Potential applications and its role in the treatment algorithms of HCC and 
metastatic disease are not yet determined (162). Complications related to the procedure are 
skin burns at the application site and osteonecrosis of ribs or vertebra along the US pathway 
(163). 
1.3.7.13 Liver transplantation for secondary tumours 
Liver transplantation for patients with unresectable liver-limited liver metastases has been 
performed with five-year OS of 60% (164). However, all patients reported in the Norwegian 
study experienced recurrence (165). 
1.3.8 Unlikely to become resectable metastases 
Patients with technically never resectable metastases are a heterogeneous group where 
tumour- and disease-related symptoms and patient-related factors determine the intensity of 










Figure 9. Case illustration 2  
55-year old male presenting with diffuse abdominal pain. On colonoscopy, a tumour is identified in the ileocecal 
valve. On imaging, metastases in the abdominal wall, adrenal glands, peritoneal carcinomatosis and multiple, 
bilateral liver metastases are detected. After multidisciplinary assessment, the patient was considered 
unresectable. 
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Figure 10 A (above left) and B (above right). Case illustration 3:  
48-year old male presenting with acute colon obstruction treated by emergency colostomy. Further imaging and 
colonoscopy revealed an adenocarcinoma of the left colon flexure and widespread liver disease. On 
multidisciplinary assessment, palliative chemotherapy was initiated. On imaging evaluation, a remarkably good 
response was noted and the patient was referred to a liver MDT for further assessment and the strategy was 
changed to curative intention. The patient underwent simultaneous resection of the primary tumour and open 
microwave ablation of 22 liver metastases including vanished lesions. Recurrence was detected four months later 
and after additional chemotherapy, right hemi-hepatectomy and re-ablation was performed. Figure 10 A (above 
left) MeVis (MeVis Medical Soulutions) reconstruction of liver with multiple tumours visible. Figure 10 B 
(above right): Post-ablation CT-scan. 
1.3.9 Different approaches in synchronous liver metastatic colorectal cancer 
If a patient presents with synchronously detected resectable liver metastases, there are three 
potential options in proceeding with resection, namely synchronous resection of liver and 
bowel tumours, surgery of the primary first or liver-first resection. The decision in favour of a 
specific strategy is dependent on the risk of complications related to the first procedure, 
anatomic location of the tumour, obstructive or anaemic symptoms from the primary tumour, 
patient comorbidity and the requirement of neo-adjuvant chemotherapy and conversion 
chemotherapy (52). A systematic review of articles comparing synchronous surgery with 
sequential bowel-first or liver-first approaches provides support for the continued use of all 
three options and similar survival in the three groups is reported (166). 
1.3.10 Resection of extrahepatic disease with concomitant liver metastases 
In a systematic review that reported on 3481 patients from 50 studies, addressing the role of 
surgery for extrahepatic disease in the presence of resectable liver metastases, a median OS of 
31 months (range 9-98 months) was found (167). Findings that OS was significantly better 
for patients who had complete liver surgery without resection of extrahepatic disease than 
those in whom liver surgery was not completed suggest that prolonged survival is possible by 
performing a hepatectomy and leaving extrahepatic disease in situ (136). In a study based on 
data from LiverMetSurvey, an international internet-based registry analysing outcomes 
following liver resection for CRCLM, patients with resectable liver- and lung metastases had 
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similar survival to patients who underwent surgery for liver only metastases (123). In a meta-
analysis reporting on OS after resection for liver metastases in the presence of extrahepatic 
disease, five-year OS was 26% for lung metastases, 17% for peritoneal metastases and 15% 
for lymph node metastases (168). 
1.3.11 Management of disappearing liver metastases 
Disappearing liver metastases refers to the inability to detect metastasis after the 
administration of pre-operative chemotherapy on imaging (complete radiological response), 
at exploration (complete clinical response) or in the resected liver (complete pathological 
response). Complete radiological response occurs in 5-37% of patients (169). Complete 
radiological response does not necessarily imply a complete clinical response and residual 
macroscopic disease is found in 25-45% at time of operation (170). Not resecting 
disappearing liver metastases is associated with an increased risk of intrahepatic recurrence 
but with no significant effect on OS (171). Microscopically residual disease was found in up 
to 80% of patients when the area of the disappearing liver metastases was included in the 
resection specimen (172). Management of disappearing liver metastases is controversial and 
possible strategies include a chemotherapy break before surgery since some disappearing 
liver metastases recur quickly, chemotherapy alone, resection with or without ablation or HAI 
therapy or resection followed by additional adjuvant chemotherapy. The current 
recommendation is that the liver resection should include the sites of disappearing liver 
metastases (170). 
 
1.4 EXTRAHEPATIC METASTASES IN COLORECTAL CANCER 
1.4.1 Lung metastases 
The lungs are the second most common site of metastasis and lung metastases occur in 10-
20% of patients with CRC (173, 174). The indications for pulmonary metastasectomy, 
established by the National Comprehensive Cancer Network Guidelines Version 2.2016 are 
as follows: 1) complete resection possible with maintenance of adequate lung function, 2) the 
primary tumour is R0 resected, 3) resectable extrapulmonary metastases do not preclude 
resection, 4) re-resection can be considered in selected patients, and 5) ablative techniques 
can be considered (175). A pre-operative CT is performed since it has a higher sensitivity 
than both chest x-ray and positron emission tomography for metastases < 1 cm. The 
specificity is however not equally high. In a systematic review of 5873 patients, 9% had 
indeterminate pulmonary nodules at chest CT of which 10.8% turned out to be metastases at 
follow-up (176).  
The surgical approach has developed from thoracotomy with lobectomy to more minimally 
invasive surgery with parenchyma-sparing procedures, such as wedge resection, precision 
excision, and segmentectomy during video-assisted thoracic surgery (177). The use of RFA 
as a treatment option for small metastases is appealing because of less reduction of lung 
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volume after treatment and the percutaneous approach with expected low morbidity (178). In 
a systematic review of eight articles including 906 patients, using percutaneous RFA for 
treatment of lung metastases, the five-year OS was 20-54% and DFS of 20-70% (179). 
However, these patients were highly selected and no cohorts exist for an adequate 
comparison. 
Most studies on pulmonary metastasectomy for lung metastases are retrospective, single-
centre reports from a time period reaching back over 20 years and are naturally afflicted by 
heterogeneous selection criteria with no regard to recent improvements in chemotherapy 
options. Outcome after pulmonary metastasectomy was assessed in a systematic review and 
meta-analysis including a total of 2925 patients and reported five-year OS ranged from 27-
68% (180). 
Factors associated with poor prognosis after pulmonary metastasectomy are mediastinal 
lymph node metastases, high CEA levels, higher number and larger size of lesions, central 
location and short disease-free interval (181). The reported recurrence rate after pulmonary 
metastasectomy is as high as 68% and most likely represents residual nodules that were too 
small to be detected prior to the resection or occult micrometastases disseminated from 
extrapulmonary organs. Multiple repeated resections of lung metastases have been 
demonstrated to be safe and effective with five-year OS after second and third resections 
being 79% and 78%, respectively (182). Multiple metastatic lung nodules are a strong 
predictor for poor outcome, but even patients with five or more lesions show an acceptable 
survival outcome with a five-year OS of 31% (177). 
1.4.2 Peritoneal metastases 
Peritoneal carcinomatosis is diagnosed in 7-13% (183) of patients with CRC and in 
approximately 25% of these patients the peritoneum is the only site of metastases (184). 
Macroscopic complete cytoreductive surgery (CRS) combined with hyperthermic 
intraperitoneal chemotherapy (HIPEC) may provide prolonged survival in selected patients 
and is now an accepted standard treatment approach. Patients treated without CRS and with 
systemic chemotherapy only, have a median survival of 12.7 months (185). In two 
retrospective multi-institutional studies and in one prospective study, CRS plus HIPEC 
resulted in a median OS ranging from 32 to 45 months with corresponding five-year OS of 
35-45% (186-188). The outcome depends on the extent of peritoneal dissemination and is 
scored using the peritoneal cancer index. A peritoneal cancer index <20, good performance 
status, postoperative chemotherapy and no synchronous liver metastases are factors 
associated with improved survival. Involvement of the lower ilium is a negative prognostic 
factor (6). Synchronous liver metastases were previously considered as a relative 
contraindication to CRS with HIPEC but more recent studies have shown similar results to 
that provided for patients with peritoneal carcinomatosis alone (189). CRS followed by 
HIPEC is performed at the expense of high morbidity and mortality, ranging from 12-52% 
and 0.9-5.8%, respectively (190). 
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1.4.3 Other distant metastases 
Distant lymph node metastases are found in 3% of patients, depending on regional lymph 
node involvement. Para-aortic lymph node metastases occur in up to 2% and resection can be 
performed with minimal morbidity and achieves a survival advantage compared with 
palliative chemotherapy (191). 
Brain metastases are detected in 0.5 to 3.2% of patients with CRC (58, 192) and are 
associated with younger age, lung metastases (concomitant in 55-85%), rectal primary and 
KRAS mutation (192, 193). Treatment of patients with isolated or symptomatic brain 
metastases can prolong survival with a reported median survival of 7.6 months after brain 
surgery if the patients received postsurgical radiotherapy (194). Treatment options include 
neurosurgery, whole brain external radiotherapy, stereotactic radiosurgery and systemic 
chemotherapy either alone or in combination. 
Bone metastases are detected in 1.5-11%, with a seemingly increasing incidence, possibly 
due to the expanding role of positron emission tomography scan and overall prolonged 
survival (58, 195). The management of skeletal metastases is usually palliative and involves 
the combination of surgery, chemotherapy and 
radiotherapy for painful lesions. Ovarian 
metastases are thought to occur in 5-10% of all 
women with metastatic cancer. It affects younger 
women more frequently, is associated with a 
reduced median survival of 19-27 months after 
detection and is linked to a poor response to 
chemotherapy (196). Metastases in the kidneys 
are considered to be extremely rare. In an 
autopsy report from 1979, 2.7% were found to 
have metastases in the kidneys (197). A more 
recent autopsy report described an incidence of 
2%-7% for kidney metastases and 5%-16% for 
adrenal gland metastases (198). Other rare 
locations for distant metastases are the spleen 
and pancreas with reported incidences of 1%-
2.8% and 1.0-2.6%, respectively (198). 
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1.5 MICROWAVE ABLATION 
Thermal ablation is becoming increasingly utilised in the treatment of HCC and metastatic 
liver tumours. It is used as definitive curative-intended treatment, as a bridge to 
transplantation in HCC and for debulking of functional neuroendocrine liver metastases for 
symptomatic relief. A number of ablation modalities have been developed and used, 
including cryoablation, ethanol ablation and laser ablation, but have been more or less 
replaced by RFA and MWA. One major drawback with thermal ablation is the high level of 
local tumour recurrence associated with the procedure. This occurs when the ablation zone 
does not completely cover the tumour with a sufficient ablation margin. Accurate placement 
of the antennae and correct estimation of the ablation volume are crucial to optimal outcome 
of ablation therapy. 
1.5.1 Microwave physics and technology 
Microwaves are a form of electromagnetic (EM) radiation with frequencies between radio 








Figure 12. Interaction between water molecules and microwave, displaying water molecule orientation.  
EM energy is created in the power generator and distributed through a coaxial cable to the 
delivering system mostly consisting of an antenna that is placed in the centre of the lesion to 
be treated. The applied high frequency (915 MHz or 2.45 GHz) EM field alternates polarity 
billions of times per second and the polar water molecules in the tissue try to continuously 
realign with the EM field, Figure 12. Heat is generated when the molecules fail to keep up 
with the alternating field and direct heating occurs in a spherical volume around the tip of the 
antenna that induces coagulative necrosis (199-201). The antenna design is needle-like and 
the antenna shaft is cooled by circulating saline or water to enable higher power and reduce 
the risk of skin burns. At the end, the ablation volume is determined by antenna design, tissue 




1.5.2 Microwave versus radiofrequency ablation 
In a recently published meta-analysis comparing RFA and MWA, one to five-year OS, DFS, 
local recurrence rate and adverse events were similar (202). Still, MWA offers theoretical 
advantages over RFA. RFA creates resistive heating when electrical current passes through 
the ionic tissue medium. It requires an electrical conductivity path and is limited in areas of 
low electrical conductivity (200). MWA, on the other hand, can heat tissue with high 
impedance and low electrical or thermal conductivity, such as bone and lung tissue. 
Microwaves can also penetrate though charred or desiccated tissue (200). The superior 
thermal properties with faster heating over a larger volume and temperatures of 160-180 C 
in contrast to 100 C with RFA makes the heat-sink effect around larger vessels less (200). 
Treatment of HCCs less than 5 mm from large vessels has proven safe and with a similar 
local tumour progression rate and survival as tumours more than 5 mm from larger vessels 
(203). The above mentioned advantages of MWA over RFA also account for some of its 
disadvantages, for example injury to adjacent vital structures due to rapid heating (204).  
RFA is thought to be more effective in HCC than in liver metastases. Because of cirrhosis 
and tumour pseudocapsules, the surrounding fibrotic liver of HCC acts as an oven, creating 
higher temperatures and prolonged cytotoxic temperatures (204). MWA produces more tissue 
and tumour contraction compared with RFA, something that needs to be accounted for during 
pre-procedural planning and when assessing treatment response (205). 
 
Figure 13. Illustration of percutaneous microwave ablation of a liver tumour. 
1.5.3 Microwave ablation – percutaneous, laparoscopic or open approach  
MWA can be performed percutaneously (Figure 13), laparoscopically (Figure 14) or during 
open surgery (Figure 15). It can be used as a unique intervention modality or synchronous to 
liver or bowel resection, depending on the clinical situation. Tumour ablation requires real-
time visualisation to localize tumours. For tumours not visible on the liver surface, imaging is 
required for tumour localization and assessment of the spatial relationship to the vascular and 
biliary structures to ensure accurate guidance and placement of the ablation device. Reports 
on the initial surgical experience with laparoscopic MWA are emerging, mostly focusing on 
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the feasibility, safety and technical success, with data on local recurrence rate and long-term 
survival being sparse (206, 207). 
 
Figure 14. Optical navigated laparoscopic microwave ablation of multiple liver metastases from colorectal 
cancer, verified with ultrasound assistance, performed at Danderyd Hospital. 
 
Figure 15. Microwave ablation of 7 colorectal cancer liver metastases during open surgery using an optical 
tracking system from Cascination AG for tumour guidance. 
1.5.4 Image guidance systems 
Navigation systems are used by the surgeon or the interventionist to target lesions and for 
intraoperative orientation. It can be used during percutaneous, laparoscopic (Figure 14) and 
open procedures (Figure 15). A reliable and accurate match between the patient’s pre-
operative imaging and the intraoperative physical space is essential in image-guided surgery. 
This is particularly challenging in laparoscopic and open surgery when soft tissue 
deformation occurs. Navigation systems are usually composed of a 3D digitizer interfaced 
with a computer that displays the actual position of the antenna with respect to cross sectional 
images of the pre-operative dataset. Accuracy is dependent on how well the antenna is 
tracked in 3D-space as well as the accuracy and precision of patient-to-image matching. 
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Tracking systems are based on acoustical, electromechanical, optical or EM systems (208). 
When using these systems, the navigated antenna still needs to be manually inserted and is 
hence afflicted by errors due to misinterpretation of displayed navigation data and unintended 
antenna bending. Free-hand insertion of the antenna is associated with prolonged procedural 
time and increased lateral error compared with using an aiming device (209). 
1.5.4.1 Ultrasound, computed tomography and magnetic resonance imaging navigation 
Percutaneous or intraoperative imaging using US is widely used as navigation modality. 
Intraoperative US has shown to be more sensitive than pre-operative imaging modalities for 
detecting small lesions (<1 cm). US has the advantage of real-time monitoring of the 
development of the ablation zone. Major limitations with US include its user dependency, the 
display of a two-dimensional image in a three-dimensional space and inability to show all 
lesions (210). CT guidance for percutaneous ablation overcomes many of the drawbacks of 
US but out-of-plane insertion of antenna is challenging and needs to be interrupted by control 
scans generating higher doses of irradiation (211). MRI provides even better imaging of soft 
tissue but requires MR-compatible equipment. Real-time fusion imaging is increasingly used, 
especially if tumours are not visible by US, and involves overlaying real-time US images 
onto a previously acquired CT or MRI during the ablation procedure (212). 
1.5.4.2 Optical tracking systems 
The tracking equipment consists of a minimum of two infrared (IR) position sensor cameras 
mounted on a trolley-stand, a probe with IR light-emitting diodes and a dynamic reference 
frame. The IR cameras have a known distance to each other and detect the optical markers, 
allowing the system to compute the actual coordinates by triangulation in real-time. The 
dynamic reference frames are attached to the patient and can thereby track the actual position 
of the patient in space by providing a spatial coordinate system relative to the patients’ 
anatomy. The major limitation of optical IR technology is the requirement of line-of-sight 
between the dynamic reference frame, the antennae and the cameras (208). 
1.5.4.3 Electromagnetic tracking 
During EM tracking, a magnetic field is generated and the ablation antenna is equipped with 
an embedded sensor from where positional information during surgery is provided (208). EM 
tracking is however sensitive to the presence of metallic objects. 
1.5.4.4 Computer-assisted navigation versus robotic systems 
Computer-assisted navigation, regardless of whether optical or EM tracking is used, is 
dependent on the interventionist to execute the antennae insertion in the defined trajectory. 
Several robotic systems for percutaneous needle-guided interventions using CT or MRI are 
commercially available and automatically orientate and drive the antenna tip to the intended 
target position (213, 214). Mean tracking error, defined as the distance between the intended 
target and the tip of the antennae, of 1.6 to 5.3 mm with robotic guidance systems (215, 216) 
and 3.6 to 3.8 mm with stereotactic navigation systems are reported (217, 218). 
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1.5.5 Microwave ablation – outcomes 
Clinical studies on outcome after MWA in CRCLM are limited and usually grouped with 
data on HCC. 
1.5.5.1 Technical success and local tumour progression 
A multi-centre study of 1007 patients with HCC from China showed a technical success of 
97.1% and a local tumour progression (LTP) rate of 5.9% (219). A similar technical success 
rate of 97.0% was seen in a study from USA involving 450 patients with both HCC and 
metastases. Local recurrence rate among all patients was 6.0% and highest for HCC (10.1%) 
and percutaneously treated lesions (14.1%) (220). A review article showed LTP rates of 5.2-
24.4% for MWA of HCC and 9.6-14.5% for liver metastases of different origins, using 
different interventional approaches and treating a wide range of tumour sizes (211). Another 
review article on ablative therapies for CRCLM, published in 2011, showed a local 
recurrence rate of 5-13% for MWA and 10-31% for RFA (221). To summarize, local 
recurrence rates vary substantially between studies with conflicting results as to which degree 
surgical approach (percutaneously, laparoscopically or open) or tumour type influence 
results. Most studies, however, report on lower rates of local recurrence in smaller tumours 
(<3 cm) (222). 
1.5.5.2 Complications 
Factors that are described to be associated with complications are tumour type, type of 
approach, number of lesions, tumour location and size, underlying liver disease, the 
interventionist’s experience and associated hepatic resection. Major complications consisting 
of biliary tract damage, haemorrhage, liver abscess, liver failure, pulmonary complications 
and perforation of adjacent viscera occur in 3-16% of cases (221). Thermal injuries to 
adjacent organs can be minimized by different displacement strategies, for example injecting 
fluid to push the ablation zone away from vulnerable structures (211). The risk for tumour 
seeding after biopsy or other needle-guided interventions of liver metastases is not negligible, 
and is estimated to occur in 0.2-4% of cases (223). Three mechanisms are described in which 
the tumour can seed the needle tract, namely on the needle itself, in bleeding created by the 
puncture, and from increased intra-tumoural pressure during the intervention (224). Post-
ablation syndrome may be the result of an inflammatory response to necrotic tissue and is 
reported to follow ablation in up to 81% of cases. It occurs from 24 to 48 hours after ablation, 
lasts up to 10 days, causing fever and flu-like symptoms like malaise, myalgia and nausea. It 
is usually self-limiting (225). 
1.5.5.3 Recurrence free survival and overall survival 
Tumour size above 3 cm is predictive of lower recurrence-free survival (220). The one-, 
three-, and five-year OS in percutaneously treated HCCs were 91.2%, 72.5% and 59.8%, 
respectively (219). In another review article on MWA of CRCLM, the mean one-, three- and 
five-year survival was 73%, 30% and 16%, respectively (221). 
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1.5.5.4 General treatment recommendations for liver metastases 
The general cut-off point for thermal ablation is a tumour diameter of 3 cm. However, 
tumours up to 5 cm are treated with acceptable results (226). Treatment of larger tumours 
comes at the cost of higher recurrence rate and incomplete ablation. 
1.5.6 Ablation versus resection in liver metastases 
Most studies demonstrate that resection is superior to RFA and that ablation should only be 
used in patients unsuitable for resection (227, 228). The question whether RFA could replace 
resection in certain clinical situations has been investigated in more recent studies. Non-
randomized comparisons of resection versus ablation are limited by patient selection, since 
patients referred for ablation usually have technical contraindications, multiple tumours or 
comorbidity, potentially reflecting a sub-group with poorer prognosis. In a propensity score 
analysis, comparing RFA with hepatectomy, RFA was inferior to resection in terms of 
survival. However, the survival curves were similar for single or small (<2 cm) metastases, 
raising the question whether ablation might be an option for single, small liver metastases 
(229). In a study comparing resection with RFA, Park et al. reported results favouring 
resection with a median survival of 56 versus 36 months for local ablation (230). Similar 
five-year OS rates of 21% for the RFA group and 23% for the resected group were reported 
by Reuter et al., with significantly fewer major complications in the ablated group (231). 
The local recurrence rate is higher following ablation but the option of a repeat intervention, 
either surgery or ablation, for recurrent disease still remains and is an important factor to 
consider in the decision-making process, especially among patients with CRCLM who most 
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1.6 THERMAL ABLATION OF HEPATOCELLULAR CARCINOMA 
HCC is the fifth most common cancer worldwide, the third cause of cancer-related death and 
accounts for more than 90% of primary liver cancers. Patients with cirrhosis are at risk of 
developing HCC and surveillance with US is currently recommended in cirrhotic patients 
who would be treated if diagnosed with the condition. Treatment of HCC is multidisciplinary, 
including hepatologists, surgeons, medical and radiation oncologists and interventional 
radiologists. Staging systems in HCC are designed to predict outcome and define treatment 
assignment. The Barcelona Clinic Liver Cancer (BCLC) classification divides HCC patients 
into five stages (0, A, B, C and D) based on the extent of disease, Child-Pugh score and 
Eastern Cooperative Oncology Group performance status, Figure 16, (232). 
Figure 16. The Barcelona Clinic Liver Cancer staging system and treatment strategy 
Surgical resection is the mainstay for treatment of HCC in non-cirrhotic or well-compensated 
cirrhotic patients and is the first treatment choice in early tumours. In well-selected patients, a 
five-year survival of 60-80% is achieved (233). Liver transplantation is the first-line 
treatment in patients with small tumours (<3 nodules <3 cm) or single tumours (<5 cm) and 
advanced liver dysfunction (Milan criteria) (234). If these criteria are followed, a five-year 
OS of 50 to 70% is achieved (235). 
Local ablation is considered the standard of care for patients with BCLC 0-A tumours not 
suitable for surgery. RFA is the most widely assessed hyperthermic ablation treatment 
modality for HCC. Survival after ablation in Child-Pugh A patients is 50-75% at five years, 
thus paralleling the outcome of surgical resection (232). Observational studies have 
demonstrated similar survival between surgical resection and thermal ablation in patients with 
small (<3 cm) HCCs (236, 237). A few randomized controlled trials have compared ablation 
versus resection, with varying results. Huang et al. found a significantly lower OS in ablated 
patients compared to resected with a higher recurrence in the RFA group (238), while Chen et 
al. found no survival differences (239). 
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2 AIMS  
 
2.1 STUDY I 
To provide detailed population-based data on the liver metastatic pattern, treatment and 
survival in metastatic CRC. 
2.2 STUDY II 
To evaluate the potentially improved resection rate of CRCLM if all patients with liver 
metastatic disease were assessed by a liver specific MDT. 
2.3 STUDY III 
To describe the feasibility and safety of a multiple MWA strategy in patients with initially 
unresectable CRCLM. 
2.4 STUDY IV 
The primary aim was to evaluate the accuracy and safety of antenna placement in stereotactic 
CT-guided MWA of primary and secondary liver tumours. Secondary aims were to evaluate 
the feasibility and radiation dose associated with the navigation system and to assess the 















3 PATIENTS AND METHODS 
3.1 STUDY I 
3.1.1.1 Study population 
All patients diagnosed with CRC in the counties of Stockholm and Gotland from the 1st of 
January 2008 to the 31th of December 2008, treated at nine different hospitals, were 
identified from the Swedish Colorectal Cancer Registry (SCCR). 
3.1.1.2 Methods – data collection 
Data on TNM stage, date and type of surgery were retrieved from the registry. All Swedish 
citizens are assigned a unique personal identification number at birth, which is also registered 
in the SCCR and was used to identify each patient in the different hospital electronic patient 
records. All clinical records were reviewed from date of diagnosis of CRC and at least five 
years afterwards, or until death. Date of diagnosis of metastatic disease was registered and 
detailed information on liver and lung metastases (number and segmental distribution) and 
the location of all other extrahepatic metastases were collected. Referral to a colorectal MDT 
and liver MDT were documented. Treatment for primary tumour and treatment of metastases, 
oncologic and surgical, were recorded. Synchronous liver metastases were defined as 
metastases detected prior to or during resection of the primary tumour, and in non-resected 
patients, as prior to or at the same time as the diagnosis of the primary tumour. Primary 
tumour location was retrieved from the electronic patient record. Midgut tumours were 
defined as tumours originating from the cecum, ascending colon and transverse colon while 
hindgut tumours were defined as tumours originating from the splenic flexure and distally. 
3.2 STUDY II 
3.2.1.1 Study population 
All patients from study I, identified with synchronous or metachronous liver metastases, 
irrespective of extrahepatic disease, detected during a five-year follow-up period, constituted 
the study cohort of study II. 
3.2.1.2 Methods – data collection 
Additional information on each patient was retrieved from the electronic patient records. 
Comorbidity according to the ASA grade, WHO performance status and relevant blood 
results (albumin, creatinine, liver enzymes and bilirubin) were documented. The discussion 
and decision made at a previous colorectal MDT and/or liver specific MDT was documented, 
as was the patient’s own preference towards treatment. Decisions made by a MDT regarding 
resectability of liver metastases were noted and patients were classified as resectable, 
potentially resectable or unresectable. 
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3.2.1.3 Evaluation of imaging studies 
All available thoraco-abdominal imaging studies were reviewed by a hepato-pancreato-
biliary-radiologist, assessing the location, number and size of intra- and extrahepatic 
metastases as well as local recurrence at the primary tumour site. For each patient, the 
imaging was classified according to a radiological classification system that was created for 
the purpose of the study, Table 6. 
Table 6. Radiology classification system designed to evaluate imaging for study II. 
Grade Description 
5 State-of-the-art (MRI with liver-specific contrast and DW imaging) 
4 Diagnostic, good technique 
3 Diagnostic, poor technique 
2 Non-diagnostic, good technique 
1 Non-diagnostic, poor technique 
Diffusion-weighted (DW). The term “diagnostic” refers to whether the imaging was sufficient to make a 
complete assessment and treatment planning. For example, a CT examination without intravenous contrast in a 
patient with innumerable metastases in all liver segments, is a “poor” technique but still diagnostic for the 
purpose of the study. 
3.2.1.4 Creation of a fictive multidisciplinary team conference 
A fictive liver MDT conference was composed, consisting of four liver surgeons, three 
medical oncologists, one diagnostic radiologist and one presenting physician. Each patient 
was presented for the audience, as he or she would have been at an actual liver MDT, 
including age, gender, medical history, existing extrahepatic disease, whether or not the 
primary tumour was resected/deemed resectable by a colorectal surgeon and if known, the 
patient’s own preference towards treatment of liver metastases. The radiologist demonstrated 
all available images and the conference participants decided on a treatment strategy for each 
patient based on the European Society for Medical Oncology (ESMO) Clinical Practice 
Guidelines for Metastatic colorectal cancer, published in 2014, dividing patients into three 
groups: resectable, potentially resectable and unlikely/never resectable (87). 
3.3 STUDY III 
3.3.1.1 Study populations 
Twenty patients with primarily unresectable liver metastases, all discussed at the regional 
liver MDT conference, who could not be rendered tumour-free because of the absence of a 
tumour-free FLR due to the extent of segmental involvement were treated with a multiple 
MWA strategy, with or without local resection. The outcome of the ablated group was 
compared with two historic cohorts selected from the study population of study I. The first 
cohort consisted of all resected patients with metastases smaller than 30 mm. The second 
cohort consisted of all patients who had been treated with palliative chemotherapy for their 
liver metastatic disease, were <85 years old, had <20 metastases smaller than 30 mm and no 
unresectable extrahepatic disease and, hence, theoretically, could have been treated with 
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thermal ablation therapy. These two groups represented the best-case and worse-case 
scenarios. 
3.3.1.2 Methods 
All interventions were done with curative intent and a prerequisite was that the whole liver 
could be rendered macroscopically tumour-free. MWA (Acculis MTA, Angiodynamics, 
Latham, NY, USA) of lesions <35 mm was performed at laparotomy with intraoperative US 
guidance (n=13) or computer-assisted navigation (n=7) (CASOne, Cascination AG, Bern, 
Switzerland) (240). Lesions engaging the liver surface were resected in some patients. 
3.4 STUDY IV 
3.4.1.1 Study population 
Twenty patients with primary or secondary liver tumours, evaluated at the regional liver 
MDT conference and assessed to have unresectable tumours or not fit for resection and 
fulfilling the inclusion/exclusion criteria, Table 7, were asked to participate in the study and 
signed the consent form after reading study information (Appendix A). Child Pugh Score 
and interpretation are outlined in Table 8. 
Table 7. Inclusion and exclusion criteria for study IV. 
Inclusion criteria Exclusion criteria 
Liver tumours not visible on US or not accessible 
by percutaneous US-guidance 
Non-correctable coagulation disorder or Child-
Pugh Score C 
Male patients > 18 years 
Non-pregnant, non-lactating females age >18 years 
Renal insufficiency (Creatinine>250) 
Condition requiring haemodialysis 
Written informed consent 
A mental condition rendering the patient unable to 
provide informed consent 
Tumours <30 mm,  
1-2 tumoursa 
 
a Progression of target tumour or additional tumours beyond the tumour-related inclusion criteria detected on the 
day of intervention were not regarded as reasons for exclusion. 
Tale 8. Child-Pugh Classification and interpretation. 
Measure 1 point 2 points 3 points 
Total bilirubin, mol/L <34 34-50 >50 
Serum albumin, g/L >35 28-35 <28 
PK (INRa) <1.7 1.7-2.3 >2.3 
Ascites None Mild Moderate to severe 
Hepatic encephalopathy None Grade I-II Grade III-IV 
 
Points Class One-year survival Two-year survival 
5-6 A 100% 85% 
7-9 B 81% 57% 
10-15 C 45% 35% 
a International normalized ratio (INR). 
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3.4.1.2 Methods - navigation system, aiming device and microwave ablation system 
A navigation system (CAS-One IR, Cascination AG, Switzerland) (Figure 17, 1) dedicated 
to stereotactic computer-assisted procedures was used. The main components of the system 
are the optical position measurement system (NDI Vicra, Northern Digital, Canada) (Figure 
17, 2), a set of retro-reflective, self-adhesive single skin markers (Figure 17, 3) and a 4-
degree of freedom aiming device (Figure 17, 4) attached to a 7-degree of freedom holding 
arm (iSYS, Medizintechnik, GmbH, Austria) (Figure 17, 5). Detailed information on the 
function of the aiming device and the advantage compared to free-hand navigation has been 
described by Wallach et al. (209). MWA was performed with a 1.8 mm water-cooled antenna 
with the use of a 2.45 GHz generator (Accu2i, Microsulis Medical) (Figure 17, 6). 
 
Figure 17. Flow-chart illustrating the procedure of study IV with detailed explanation in the text. 
3.4.1.3 Patient set-up 
The patients were placed on the CT table in a supine position. General anaesthesia with 
intermittent intravenous neuromuscular block allowed immobilization. High-frequency jet 
ventilation (HFJV) (Monsoon III ventilator, Acutronic Medical Systems AG, Hirzel, 
Switzerland) was used to minimize ventilation-induced liver movement. HFJV is a method 
for mechanical ventilation where short-duration pulses of pressurized gas are delivered in a 
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high-flow manner through a small catheter in the trachea (241). Adequate intraoperative 
monitoring and expiratory CO2 measurements were performed to enable adjustments of 
HFJV settings and avoid hypercapnia. 
3.4.1.4 Procedure 
Self-adhesive reflective single markers were glued onto the patient’s skin, enabling both 
automatic image-to-patient registration and continuous tracking of patient surface 
deformation and movement (Figure 17, 3). CT images with complete liver coverage were 
acquired during HFJV and transferred to the navigation system (Figure 17, 1). On the 
navigation system, target locations (Figure 17, 7) as well as the most appropriate antenna 
trajectory (Figure 17, 8), avoiding ribs, lungs and major bile ducts and vessels were 
identified manually and displayed in a 3D off-plane reconstruction. A pre-calibrated dynamic 
reference base (Figure 17, 9) was placed in the antenna guide adapter (Figure 17, 10) and 
roughly positioned along the planned antenna insertion point, with the help of a 3D 
reconstruction of the skin surface presented on the screen and a 2D targeting viewer (Figure 
17, 11) for fine alignment. The dynamic reference base was then replaced by an antenna 
guide (Figure 17, 12) through which the MW-antenna (Figure 17, 13) was inserted to the 
planned depth with the active point of the antenna in the centre of the lesion. A control CT 
was performed and if the antenna was assessed as accurately placed, MWA was conducted, 
and if located non-optimally, the antenna was repositioned. Ablation time and energy was 
calculated based on tumour size and proximity to vascular and biliary structures, according to 
the manufacturer’s guidelines and operator discretion. 
3.4.1.5 Post-procedural follow-up 
After the intervention, the patient was transferred to the post-operative ward and discharged 
the same or following day. A control CT was performed at day 5-10, to evaluate the ablation 
zone, and then repeatedly according to local follow-up guidelines with MRI or CT depending 
on the type of malignancy. Perioperative morbidity was assessed 30 days post-ablation when 
a follow-up visit was scheduled. 
 
Figure 18 (right). Intraoperative validation module. Yellow 
hair-cross is the target and orange hair-cross corresponds to 
the actual antenna tip. Figure 19 (above left). Illustration of 
different components in target positioning error. 
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3.4.1.6 Data analysis 
Antenna insertion accuracy was evaluated retrospectively with an intraoperative validation 
module integrated into the navigation system, Figure 18. The intraoperative validation 
module fuses post-insertion control CT with pre-insertion navigation/planning CT and 
compares the planned trajectory with the achieved antenna position and calculates the target 
positioning error (TPE) – the euclidean distance between the actual antenna tip position 
measured on the control CT and the desired antenna position defined pre-operatively on the 
navigation CT, Figure 19. Additional study endpoints are outlined in Table 9. 








Tumour size Maximum tumour diameter 
Tumour location depth Distance between antenna’s skin-entry point and the 
intended target 
Cranio-caudal orientation angle Antenna trajectory orientation angle on the sagittal 
plane defined by y-z axis of the patient coordinate 
system 
Orbital orientation angle Antenna trajectory orientation angle on the axial plane 
defined by x-y axis of the patient coordinate system 
Procedure time Duration from the acquisition of the first planning 
scan to the withdrawal of the antenna; including 
planning, preparation time, aiming device alignment, 
needle insertion, and ablation time (minutes) 
Number of complications Number of intervention-related complications, 
according to standardized SIR classification system 
(242) 
Patient radiation exposure Radiation exposure expressed as dose-length product 
(DLP) 
Lateral error A normal distance between the planned trajectory and 
the antenna at the planned target position 
Depth error A longitudinal distance from the antenna tip to the 
target along the planned trajectory 
Total error Euclidean distance between the achieved antenna tip 
position and the planned target position 
Angular error A deviation between the planned trajectory axis and 
the achieved antenna axis 
Number of antenna readjustments Number of times the needle was repositioned to better 
target the intended target area 
Dose-length product (DLP) CTDIvol (a measure of exposure per slice) x irradiated 
length. DLPtotal = total radiation dose. DLPinter = an 
interventional dose corresponds to the radiation 
introduced by antenna verification scans  
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3.5 STATISTICS 
For studies I, II, III and IV, p-values < 0.05 were considered statistically significant. Kaplan-
Meier plots were used to display survival probabilities and log-rank test for testing equality of 
survival functions between groups in studies I, II and III. For studies I and II, statistical 
analyses were performed using STATA 13 and for studies III and IV, STATA 10 was used 
(StataCorp, College Station, Texas 77845 USA). 
3.5.1.1 Study I 
Categorical data were presented as frequencies/proportions and analysed with Pearson’s chi-
square test. Continuous variables (age) were described as medians and analysed with the 
Wilcoxon rank-sum test (non-normally distributed data). Logistic regression was used to 
calculate unadjusted and adjusted odds ratios (ORs) for factors associated with the probability 
of undergoing a liver intervention, controlling for possible confounders hypothesized as being 
age (dichotomized into ≤ or >68 [median]), sex, tumour stage (dichotomized as T1/T2 and 
T3/T4), nodal status (dichotomized as N0 and N1/N2), synchronous/metachronous and 
number of liver metastases (categorized into 1-2, 3-4 and ≥5 lesions). Variables with p<0.10 
in the univariable analyses were included in the multivariable analysis and presented with a 
95% confidence interval (CI). The Cox proportional hazards model was used to identify risk 
factors affecting survival, calculating hazard ratios with 95% CI. Potential risk factors 
included in the model were age (continuous variable), sex, tumour and nodal stage 
(dichotomized as described above), primary tumour origin (midgut/hindgut), presence of liver 
metastases, lung metastases and extrahepatic disease. In patients with liver metastases, 
included risk factors were age, sex, tumour and nodal stage (as above), primary tumour origin 
(midgut/hindgut), synchronous versus metachronous detection, size of liver metastases 
(dichotomized into ≤50 mm and >50 mm), number of liver metastases (categorized as above), 
liver resection and the presence of lung metastases. 
3.5.1.2 Study II 
Baseline characteristics were assessed and tested as described for study I. Logistic regression 
was used to calculate ORs for factors predictive of referral to the liver MDT conference, 
adjusting for age (dichotomized into ≤ or >68 [median]), sex, ASA grade, treatment at a 
teaching hospital, synchronous/metachronous and number of liver metastases (categorized 
into 1-5, 6-10 and >10 liver metastases). Variables with p <0.15 in the univariable analysis 
were included in the multivariable model. Cohen’s Kappa for interrater agreement was used 
to determine the overall agreement between the original and fictive liver MDT conference, 
analysing resectable/potentially resectable versus unresectable, and κ>0.7 was considered 
acceptable. 
3.5.1.3 Study III 
Baseline characteristics were defined and analysed as described for study I with the addition 
of Fisher’s exact test for proportions. Cox proportional hazards model was used to identify 
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independent predictors of survival. The two predictors with the lowest p-values were kept in 
the multivariable analysis. 
3.5.1.4 Study IV 
Patient and tumour characteristics and target errors were presented with mean (SD), 
frequencies (percentage) and median (min-max). Correlation between tumour location depth 
and targeting accuracy was tested with the nonparametric Spearman rank correlation test. A 
power calculation was performed based on previous experiments on cadavers where a TPE of 
3.1  1.2 mm was achieved. An inferior TPE of 4.0  1.2 was expected in humans. The 
power calculation revealed that a sample size of 16 was required to achieve a power of 0.8 at 
a significance level of 0.05. The study was oversampled by four patients to cover for potential 
loss. 
3.6 ETHICS 
The regional ethical review board at Karolinska Institutet, Stockholm, approved studies I, II, 



















4.1 STUDY I 
During 2008, a total of 1026 patients were diagnosed with CRC of whom 52.7% were male 
and 47.3% female with males being significantly younger than females (p<0.001). 
4.1.1.1 Liver metastatic patterns 
During a median follow-up of 63 months, liver metastases were detected in 272 (26.5%) 
patients and more often in males than females (29.0% versus 23.7%, p=0.054) with no 
observed age difference (p=0.397). The demographic and clinico-pathological features of 
patients with and without liver metastases are outlined in Table 10. Patients with hindgut 
cancer were significantly more often diagnosed with liver metastases than patients with 
midgut cancer (28.4% versus 22.1%, p=0.029). However, patients with liver metastatic 
midgut cancer had a higher tumour burden in terms of number of liver metastases and extent 
of segmental involvement. 
Patients with synchronously detected liver metastases (16.2%) had a higher tumour burden 
than patients with metachronous detected metastases (10.3%) (>4 metastases: 67.5% versus 
34.0%, p<0.001 and 7 to 8 segments: 39.8% versus 13.2%, p<0.001). Synchronous versus 
metachronous detection of liver metastases was not influenced by age (p=0.950), sex 
(p=0.478) or embryologic (p=0.096) or anatomical origin (p=0.127) of the primary cancer. 
Seventy-six percent of all detected liver metastases were diagnosed within one year, 89% 
within two years and 93% within three years of diagnosis of primary tumour. At detection of 
liver metastases, 81 patients (48.8% of those with synchronous liver metastases) had liver-
only metastases and 60 patients had widespread metastases engaging all liver segments. One 
hundred and three patients (37.9%) had liver-only metastases and no further extrahepatic 
metastases detected during the follow-up period. 
4.1.1.2 Extrahepatic metastases 
Extrahepatic metastases were diagnosed in 251 patients (24.5%). The most common 
extrahepatic site was the lungs (174 patients, 16.9%), followed by peritoneal carcinomatosis 
(73 patients, 7.1%) and distant lymph nodes (49 patients, 4.8%). Lung metastases were 
significantly more often diagnosed in patients with metachronously detected liver metastases 
(56.6% versus 44.0%, p=0.042). Fifty-one percent of lung metastases were diagnosed within 
one year, 75% within two years and 84% within three years from diagnosis of the primary 
tumour. Patients with hindgut cancer were more often diagnosed with lung metastases (19.7% 
versus 13.2%, p=0.010) and peritoneal carcinomatosis was more frequent in midgut cancer 
(10.6% versus 5.5%, p=0.003). 
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Age (years)c 71.0 (62.2-79.9)  71.9 (63.5-81.0) 68.0 (60.1-77.4) <0.001b 
     Male 69.8 (62.1-77.5)  70.5 (62.3-78.1) 67.5 (60.3-75.1)  0.021b 
     Female 72.6 (63.3-83.2)  74.2 (65.4-84.1) 68.9 (59.4-79.9) 0.001b 
Age category      
     <50 55 (5.4)  35 (4.6) 20 (7.4) 
0.001 
     51-65 306 (29.8)  206 (27.3) 100 (36.8) 
     66-80 413 (40.3)  309 (41.0) 104 (38.2) 
     >80 252 (24.5)  204 (27.1) 48 (17.6) 
Sex ratio (M : F) 541 : 485  384:370 157 : 115 0.054 
Primary tumour position d 
     Midgut tumours 349 (34.9)  272 (36.9) 77 (29.4) 
0.029 
     Hindgut tumours 651 (65.1)  466 (63.1) 185 (70.6) 
Tumour category e 
T0 12 (1.2)  11 (1.5) 1 (0.4)  
T1 90 (8.8)  85 (11.3) 5 (1.8) 
<0.001 
T2 145 (14.1)  138 (18.3) 7 (2.6) 
T3 520 (50.7)  389 (51.6) 131 (48.2) 
T4 201 (19.6)  105 (13.9) 96 (35.3) 
Unknown 58 (5.6)  26 (3.4) 32 (11.7)  
Node category e  
N0 513 (50.0)  470 (62.3) 43 (15.8) 
<0.001 N1 333 (32.5)  192 (25.5) 141 (51.8) 
N2 82 (8.0)  45 (6.0) 37 (13.6) 
Unknown 98 (9.5)  47 (6.2) 51 (18.8)  
Metastatic category e                                                                                                                                                                                       <0.001        
M0 773 (75.4)  689 (91.4) 84 (30.9) 
<0.001        
M1 224 (21.8)  37 (4.9) 187 (68.8) 
Unknown 29 (2.8)  28 (3.7) 1 (0.3)  
TNM-stage e  
Stage I 194 (18.9)  191 (25.3) 3 (1.1) 
<0.001 
Stage II 299 (29.1)  274 (36.4) 25 (9.1) 
Stage III 267 (26.0)  213 (28.2) 54 (19.9) 
Stage IV 224 (21.8)  37 (4.9) 187 (68.8) 
Unknown 42 (0.4)  39 (5.2) 3 (1.1)  
Values in parentheses are percentages unless indicated otherwise. aChi2 test, except bWilcoxon rank-sum test. 
cValues are median (i.q.r). dAccording to embryologic origin excluding unknown primaries (n=11) and multiple 
primaries (n=15). eStage at initial diagnosis. 
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4.1.1.3 Treatment of liver and extrahepatic metastases 
Of all patients with liver metastases, 102 (37.5%) were referred to the liver multidisciplinary 
team conference and 69 (25.4%) were treated with resection, ablation or a combination of the 
two methods, with a recurrence rate of 42%. Of the 251 patients where extrahepatic 
metastases were detected, 30 (12%) were resected/ablated with curative intent. The 
probability of undergoing a liver resection was associated with age ≤68 years (OR 2.79, CI 
1.37-5.69), T-stage (T3-T4 versus T1-T2, OR 0.15, CI 0.03-0.77) and number of liver 
metastases (>5 versus 1-2, OR 0.07, CI 0.02-0.18) while in the multivariable analysis sex, 
metachronous presentation and nodal stage was not. 
4.1.1.4 Survival 
Five-year OS in the entire cohort was 56.2% (median survival not reached). Patients with 
liver metastases had a significantly lower five-year OS compared to patients without liver 
metastases (16.9% versus 70.4%, p=0.001).  
Factors identified as poor predictors of survival in the multivariable analysis among patients 
with CRC were increasing age (HR 1.04, CI 1.03-1.05), higher T-stage (T3-T4 versus T1-T2, 
HR 1.40, CI 1.01-1.93) and higher N-stage (N1-N2 versus N0, HR 1.62, CI 1.29-2.04), as 
well as the presence of liver metastases (HR 3.38, CI 2.57-4.44) and extrahepatic metastases 
(non-lung metastases, HR 2.05, CI 1.56-2.69). Sex (HR 1.09, CI 0.91-1.30), the presence of 
lung metastases (HR 1.23, CI 0.93-1.62) and primary tumour location (HR 0.90, CI 0.74-
1.09) were not significantly associated with survival. In the multivariable analysis of patients 
with liver metastases, higher age (HR 1.03, CI 1.01-1.05), hindgut tumour origin (HR 0.56, 
CI 0.39-0.79), size of liver metastases > 50 mm (HR 2.51, CI 1.73-3.65) and liver resection 
(HR 0.21, CI 0.13-0.33) remained significant predictors of survival. Also in this setting, the 
presence of lung metastases (HR 1.11, CI 0.80-1.53) and sex (HR 0.91, CI 0.65-1.28) did not 
influence OS. 
In patients with liver metastases, midgut cancers had a significantly worse OS compared to 
hindgut cancers with a two-year survival of 22.1% and 51.9%, respectively, and a five-year 




Figure 20. Kaplan-Meier curves 
showing overall survival in patients with 
midgut and hindgut tumours with or 
without liver metastases (LM). 
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The same survival pattern was seen in patients with lung metastases with a five-year survival 
of 13.0% versus 21.9% (midgut versus hindgut origin, p=0.008). 
The one- and five-year survival rates of patients with liver metastases treated with resection, 
palliative chemotherapy or best supportive care were 92.8% and 48.6%, 58.1% and 2.2%, and 










Figure 21. Kaplan-Meier curves showing overall survival in patients with liver metastases treated with curative-
intended intervention, palliative chemotherapy or best supportive care (BSC). 
In Figure 22, survival of patients with non-metastatic CRC is compared to patients with 
different metastatic patterns in terms of liver and lung metastases. Patients without metastatic 
disease had a five-year survival of 75% compared with 45.7%, 25.2% and 12.7%, 
respectively, for patients with lung metastases only, liver metastases only, and liver and lung 










Figure 22. Kaplan-Meier curves showing overall survival in patients with non-metastatic colorectal cancer and 
different metastatic pattern. 
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4.2 STUDY II 
4.2.1.1 Results from the original liver multidisciplinary team conference 
Of 1026 patients diagnosed with CRC during 2008, 272 developed liver metastases of which 
235 patients were evaluated at a colorectal MDT and 102 were further referred and discussed 
at a liver MDT conference, Figure 23. Out of the 133 patients not referred to the liver MDT, 
55 were considered by the local colorectal team as to have unresectable liver metastases, 26 
as having unresectable extrahepatic disease, 42 as having a combination of both unresectable 
liver and extrahepatic disease and the remaining were not referred for a variety of other 
reasons. Thirty-seven were not evaluated in a MDT setting at all. 
Factors associated with the referral to a liver MDT were age (OR 3.12, CI 1.72-5.65), ASA 
score (ASA 2 versus 3, OR 0.34, CI 0.18-0.63) and number of liver metastases (1-5 versus 6-
10 and >10, OR 0.16 (CI 0.06-0.41) and OR 0.10 (CI 0.04-0.22), respectively). Sex, 
treatment at a teaching hospital, and metachronous detection did not influence the referral 
rate. 
Referral rate to the liver MDT ranged from 0% to 48.6% between the different hospitals of 
the region. When excluding two hospitals which treated less than 10 patients with liver 
metastases, the referral rate ranged between 28.6% and 48.6% (p=0.505). 
 
 
Figure 23. Flow-chart illustrating the decisions made at the original liver MDT and at the fictive liver MDT 
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4.2.1.2 Results from the fictive liver MDT conference 
Imaging for re-evaluation could not be retrieved for six patients who were then excluded 
from the analysis. Results from the fictive liver MDT are shown in Figure 23. Twenty-two 
out of 170 patients originally not managed by a hepatobiliary surgeon, were assessed as 
resectable/potentially resectable at the fictive liver MDT. These 22 patients as a group had a 
higher median age (p=0.005), a higher proportion of emergency surgery of the primary 
tumour (p=0.002) and higher proportion of patients with more than 5 liver metastases 
compared with the patients that were actually referred to the liver MDT. However, ASA 
score (p=0.523) and synchronous detection (p=0.361) did not differ. Median OS among the 
22 patients was 12 months compared with 55.9 months for patients originally discussed at a 
liver MDT and resected and 19.4 months for patients originally discussed at a liver MDT and 
not resected. 
Primary reasons for unresectability (n=158), as assessed at the fictive liver MDT were 
extrahepatic disease (n=40), extent of liver metastases (n=39), a combination of extensive 
liver and extrahepatic disease (n=34), unresectable CRC or unresectable local recurrence 
(n=20), comorbidity (n=12), age (n=8) and patient preference (n=5). 
Actual treatment decisions among those with resectable or potentially resectable liver 
metastases made at the original liver MDT and during the fictive liver MDT were the same in 
95.1% of patients (Cohens’s Kappa 0.83). The original and fictive liver MDT conferences 
disagreed on the management of five patients (Figure 23). One patient, assessed as 
potentially resectable with local ablation at the original liver MDT conference were not 
assessed as even potentially resectable at the fictive liver MDT. On the contrary, four patients 
were evaluated as potentially resectable at the fictive liver MDT, but not at the original liver 
MDT conference. The motivations for the decisions at the original MDT were bilateral 
disease, a too small FLR, one complicated located LM and the last patient as unresectable 
because of extrahepatic disease (a single lung metastasis and a single metastasis of the 
abdominal wall). 
The quality of liver imaging is outlined in Table 11. 
Table 11. Classification of imaging in 266 patients with liver metastases 
Grade Description Distribution in study population n (%) 
5 State-of-the-art (MRI with liver-specific contrast and DW 
imaging) 
3 (1.1) 
4 Diagnostic, good technique 189 (71.1) 
3 Diagnostic, poor technique 27 (10.1) 
2 Non-diagnostic, good technique 45 (16.9) 
1 Non-diagnostic, poor technique 2 (0.8) 




4.3 STUDY III 
4.3.1.1 Patients' treatment outcome 
Twenty patients with multiple CRCLM were treated with the multiple MWA strategy 
between October 2009 and September 2012. The control groups consisted of 25 palliatively 
treated and 36 resected patients selected from the 272 patients with liver metastases in the 
five-year follow-up of 1026 patients presenting with CRC during 2008 from study I. Patient 
and tumour characteristics are presented in Table 12 and treatment-related parameters in the 
multiple MWA strategy-group in Table 13. Simultaneous local resection of metastases was 
performed in four patients. In one patient, the strategy was changed intraoperatively from the 
MWA strategy to a two-stage procedure with initial clearance of the left liver followed by a 
right hemihepatectomy at a later stage. Major complications (Clavien-Dindo classification 3-
4) occurred in five patients. One patient suffered from multiple liver abscesses and another 
developed a pleural effusion, both of which were treated with percutaneous drainage. Three 
patients had respiratory failure treated with non-invasive ventilation support. 








Age (years), median 
(min-max) 
64 (44-82) 65 (42-83) 68 (49-83) 0.75 
Male : female 9 : 11 23 : 13 15 : 10 0.38 
Synchronous/ 
metachronous 
18 : 2 17 : 19 15 : 10 <0.05 
Number, median (min-
max) 
9 (5-22) 2 (1-15) 5 (1-16) <0.05 
Size (mm)a, median 
(min-max) 
27 (10-54) 17 (6-30) 19 (10-28) 0.07 
 aSize at initial presentation. bMWA group versus palliative group. 
Table 13. Treatment-related parameters in the MWA group 
  
Number of ablations 7 (4-22) 
Procedure time (min) 235 (112-475) 
Length of hospital stay (days) 10 (2-24) 
  








Minor (Grade 1-2) 7 
Major (Grade 3-4) 5 
Values in parenthesis are min-max. aAccording to the Clavien-Dindo classification. 
Hepatic recurrence occurred in 17 patients of whom five also had local recurrence at a 
previously ablated site. Extrahepatic recurrence was detected in 11 patients, all except one in 
patients with hepatic recurrence. Seven patients underwent re-resection and five were re-
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ablated, Table 14. All patients who died during the follow-up period (n=10) had hepatic 
recurrence and eight of them had extrahepatic recurrence. 
Table 14. Recurrence patterns and re-resection. 
 
Recurrence patterns and re-resection n=20 
Hepatic recurrence  
Local recurrence 5 (25.0) 
New recurrence 17 (85.0) 
Extrahepatic recurrence 11 (55.0) 
  
Re-resection for hepatic recurrence 7 
Re-ablation of hepatic recurrence 5 
Values in parenthesis are percentages. 
4.3.1.2 Survival 
Ten patients were alive after a median follow-up of 25 months (9-54). Four-year survival in 
the resected and palliative treated groups were 70% and 4%, respectively. Patients assigned 
for the MWA strategy had a four-year survival of 41%, a significant difference compared 










Figure 24. Survival curves in the three studied cohorts 
 
In Cox regression analysis on factors influencing survival, only treatment strategy was 
significant (MWA versus palliative group, HR 0.56, CI 0.33-0.96). Age, gender, radiological 
T-stage of the primary tumour, maximum size of metastases, number of metastases and 
synchronous versus metachronous detection were not significant predictors of survival. 
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4.4  STUDY IV 
From March 2013 to January 2014, 20 patients were enrolled in the study. Due to technical 
issues, a free-hand insertion technique was used in three patients, and they were subsequently 
excluded from the performance data analysis. Patient and tumour characteristics for the 17 
patients with 25 tumours are presented in Table 15. The lesions were located in all segments 
except segment one. 
Table 15. Patient and tumour characteristics for patients included in the study. 
Patient and tumour characteristics Value 
Gender (male : female) 13 : 4 
Age (year) (SD) 69.6  9.2 
Previous interventions, no. (%) of patients 15 (88.2) 
Ablation 7 (46.7) 
Resection 1 (6.6) 
Ablation and resection 7 (46.7) 
No. of previous interventions (min-max) 1 (0-3) 
No. of tumours, median (min-max) 1 (1-3) 
Tumour type, no. (%) of patients  
Hepatocellular carcinoma 11 (64.7) 
Colorectal liver metastases 5 (29.4) 
Gastrointestinal stromal tumour metastasis 1 (5.9) 
Tumour diameter (mm), mean (SD) 14.9  5.9 
Tumour location depth (mm), mean (SD) 87.5  27.3 
Craniocaudal orientation angle (), min-max -1.3 to 26.9 
Orbital orientation angles (), min-max -30 to 58.2 
4.4.1.1 Targeting accuracy 
The targeting accuracy was 5.8  3.2 mm with one antenna readjustment. Lateral, depth, and 
angular errors were 4.0  2.5 mm, 3.4  3.2 mm, and 2.7  2.9, respectively. No correlation 
between tumour location depth and targeting accuracy was seen (Spearman =0.2; p=0.3). 
4.4.1.2 Safety of the procedure and HFJV 
Complications during and after treatment were registered using the Society of Interventional 
Radiology (SIR) classification (242). Two patients had minor complications none of which 
were related to the use of HFJV. One patient, treated for a subcapsular tumour, was 
readmitted for chest wall pain and treated with analgesics (SIR class B complication) and the 
second patient suffered from a minor skin burn from the MWA antenna (SIR class B 
complication). 
4.4.1.3 Feasibility and radiation dose 
Technical failure with the aiming device occurred in three patients, omitting the use of the 
aiming device. In two patients with tumours located in the lateroposterior section, the 
angulation of the antenna path was outside the range of the aiming device. After these 
incidences, patients with tumours in the laterposterior part were placed in a left 45 rotation to 
enable better access. In the third case, the thread between the carbon plate (placed under the 
patient, its function being to hold the holding arm) and the holding arm broke. The thread was 
replaced with a more rigid construction. 
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Median procedural time was 39.5 min (26-89) for one antenna placement and 70 min (56-
126) for two or more antennae placements. Median post-treatment hospital stay was one day 
(range 1-2 days). 
Total radiation dose and interventional dose is outlined in Table 16. Two different scanning 
protocols were used for HCC and liver metastases, which are reported separately. 
Table 16. Patient radiation dose 
Tumour type Radiation dose, mGy x cm, mean (SD) 
Hepatocellular carcinoma  
DLPtotal 1154  594 
DLPinter 502  326 
Liver metastases  
DLPtotal 597  208 
DLPinter 264  121 





















5.1 INCIDENCE OF LIVER METASTASES  
The incidence of liver metastases, 26.5%, was found to be lower than often cited but 
concurrent with other incidence data from previously published population-based studies (50, 
51). Approximately half of all patients with liver metastases had liver-only metastases at 
detection and one third had widespread disease at diagnosis. 
5.2 DIFFERENCE IN METASTATIC PATTERN AND SURVIVAL IN MIDGUT VS. 
HINDGUT CANCER 
Patients diagnosed with liver metastases secondary to a midgut cancer had a higher TNM-
stage at diagnosis but despite that, CRC originating in the hindgut had a higher incidence of 
liver metastases. Once liver metastases were detected, the extent of segmental involvement 
and number of metastases were more pronounced in midgut cancer. Lung metastases were 
more often diagnosed in hindgut cancer and peritoneal metastases more often in midgut 
cancer. This study also confirms the higher proportion of liver metastases among younger 
patients, potentially attributable to both patient and doctor delay. Reports on whether 
incidences of liver metastases are dependent on primary tumour location are inconsistent. 
Two studies, one German and one study based on data from the Surveillance, Epidemiology, 
and End Results (SEER) database showed a higher incidence of liver metastases in colon 
cancer as compared to rectal cancer. However, the German study (56) only included patients 
with synchronously detected liver metastases in surgically treated CRC and the SEER data 
base is limited to metastases registered at the time of CRC diagnosis (58). In another study by 
Lee et al., no difference in hepatic spread was detected (59). In a Norwegian study that also 
only included curatively treated CRC patients, left-sided colon cancer was found to be 
associated with an increased risk of metastatic spread to the liver (60). 
OS was significantly lower in patients with liver metastatic midgut cancer compared with 
hindgut cancer. This is in keeping with other reports of inferior survival of right-sided colon 
cancer in the presence of metastatic disease (103, 243, 244). Many reports on the subject 
focus on potential differences in survival between right-sided and left-sided cancer in non-
metastatic CRC, and also in this respect, contradictory data is reported. A recently published 
meta-analysis showed that right-sided cancer was a significant risk factor for death in 
Western countries, making lifestyle, health-care utilization, and genetic background potential 
factors contributing to the issue (43). A more advanced tumour stage was seen in patients 
with midgut cancer, which is in agreement with other publications (42) and potentially 
mirrors later diagnosis of right-sided cancer and consequent lead-time bias. To investigate 
mortality by stage, Weiss et al. adjusted for multiple patient and tumour factors and evidently 
found no overall difference in five-year mortality between right- and left-sided colon cancer. 
However, the study was limited to stage I-III and only curatively resected patients were 
included. In a subgroup analysis of stage III disease, right-sided cancers had a shorter survival 
(245). The SEER data base was yet again used when Meguid et al. found a persistent 
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significant difference with a 5% increased mortality risk in right-sided colon cancer when 
controlling for multiple factors, including stage (246). Patients with right-sided cancer have 
been found to be older (43) and suffering from more comorbidities (247) and, consequently, 
these patients are not treated with adjuvant chemotherapy to the same extent. Since the 
incidence of right-sided cancer is increasing, these results might have clinical implications. It 
is likely that there are differences in oncological outcome based on tumour location since 
right-sided cancer is associated with high MSI and CpG island methylation, whereas left-
sided cancer more often shows chromosomal instability, factors known to affect the success 
of chemotherapy regimens. 
The present study failed to show any survival difference between midgut and hindgut cancer 
in the overall cohort, only among patients with liver metastases.  
5.3 SURVIVAL IN METASTATIC COLORECTAL CANCER 
Patients with lung-only metastases had a three times longer median survival than patients 
with liver only metastases and in proportional hazard regression analysis, the presence of 
lung metastases did not influence OS, neither in the entire cohort nor among patients with 
simultaneous liver metastases. In patients with liver metastases lung metastases are known to 
be associated with better outcome compared with other extrahepatic sites (167). Based on 
these results, one could speculate on the benefit of performing liver resections on patients 
with concomitant unresectable lung metastases. In a report by Dave et al., patients scheduled 
for resection of liver and lung metastases, who for some reason never underwent resection of 
lung metastases (due to progression of lung metastases or recurrent liver metastases) still had 
a five-year survival rate of 30% (248). Andreas and colleagues found that patients with 
simultaneously diagnosed liver and lung metastases, and resected for both metastatic sites, 
had a similar OS to those who had undergone resection of isolated liver metastases (123). The 
survival was found to be even greater in patients resected for liver plus lung metastases as 
opposed to patients who underwent resection of liver-only metastases (122). Contradictory 
results are presented by Nordholm-Carstensen in a large Danish nationwide study where the 
occurrence of synchronous lung metastases had a profound impact on survival (249). 
5.4 THE IMPACT OF A LIVER MULTIDISCIPLINARY TEAM CONFERENCE 
Several publications have, in different ways, emphasized the importance of a dedicated 
hepatobiliary team in the management of liver metastatic CRC in terms of higher resection 
rate and improved DFS and OS (72, 74-76). Study II differs from previous publications since 
the re-evaluations were done on all patients with liver metastases originating from a 
population-based cohort, including patients with extrahepatic metastases and accounting for 
comorbidity and patient’s own preferences towards treatment.  
Twenty-two patients (12.9%) that had not been assessed by a hepatobiliary surgeon were 
assessed as resectable/potentially resectable at the fictive liver MDT. Two were assessed by a 
medical oncologist only and three were managed by a colorectal surgeon outside a colorectal 
MDT, the remaining seventeen were evaluated at the colorectal MDT as having unresectable 
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liver metastases. These twenty-two patients were older and a larger proportion had five or 
more liver metastases compared with those referred to the actual liver MDT, but they did not 
differ in ASA grade. One must though bear in mind the possibility of other factors not clearly 
identified in study II that would have limited the number of these patients that eventually 
would have undergone surgery. Consistency in decision-making in patients considered 
resectable/potentially resectable and not resectable at the actual and fictive liver MDT were 
evaluated with Cohen’s kappa, measuring the interrater agreement to 0.83, which is 
considered acceptable. 
In a study by Young et al., management decisions differed between colorectal and liver 
specialists in almost 50% of patients (81). Decision-making by non-liver surgeons was 
evaluated by Jones et al., who found that almost two-thirds of patients, treated with palliative 
chemotherapy, were assessed as potentially resectable by a group of experienced liver 
surgeons (250). The Jones study was limited to patients treated with palliative chemotherapy 
and liver-only metastases and in the study by Young et al., only radiology was re-evaluated. 
Thillai et al. reported that a third of patients with liver-limited diseases were never referred to 
a liver MDT (251). 
The re-evaluated population of study II were generally well treated with high referral rates 
and resection rates to start with. Despite that, an additional 22 patients were found 
resectable/potentially resectable resulting in a hypothetical resection rate of nearly 40%. 
Liver imaging was non-diagnostic for 17.7% of the re-evaluated patients, referring solely to 
liver imaging. Mostly, other factors such as resectablilty of the primary tumour, the extent of 
extrahepatic metastases or comorbidity nevertheless made decision-making possible. In a few 
cases, MRI without liver-specific contrast and diffusion-weighted imaging, only displaying a 
small number of metastases was considered as resectable even though it would not have been 
sufficient for a decision in 2017, when state-of-the art MRI is almost mandatory. 
5.5 VARIATIONS IN REFERRAL PRACTICE TO A LIVER MULTIDISCIPLINARY 
TEAM CONFERENCE 
Factors found to be associated with referral were age, ASA score and number of liver 
metastases, similar factors identified by Ksienski et al. (252). 
Referral rates varied between hospitals (0-48 %) in study II, a seemingly large difference but 
statistically non-significant. Marked differences in referral practice are seen in numerous 
other studies (74, 80, 81, 252). Economic and resource constraints, local medical expertise, 
lack of physician engagement and time, have all been identified as barriers for proper referral 
(77). Since no clear guidelines exist to facilitate the assessment of referral to a liver MDT, in 
the worst case, referral might be dependent on the treating physician’s knowledge on updated 
resection criteria. Differences in referral rates could also be explained by factors other than 
type of hospital, such as patient co-morbidity, patient preference and the arrangements around 
multidisciplinary team meetings. 
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5.6 FEASIBILITY OF A MULTIPLE ABLATION STRATEGY 
The multiple MWA approach in study III, including re-resection and re-ablation, rendered a 
group of patients tumour-free with major complication rates of 25%. The four-year OS in the 
multiple MWA group was significantly better than the historic group treated with palliative 
chemotherapy. 
Thermal ablation (RFA) has been shown to be inferior to resection (227-229) but is better 
than palliative chemotherapy alone regarding survival (148, 221). The concept of study III 
highlights ablation as an alternative first-line treatment strategy in patients with potentially 
resectable or unresectable metastases. In patients with a high risk of recurrence (multiple 
lesions and synchronously detected metastases) major resections may render further 
interventions impossible due to limited technical options. By adopting a multiple ablation 
strategy, all treatment options including resection and re-ablation are still available. 
Recurrence rate after liver resection is reported to range from 56.7 to 63% within two years 
(85). In study III, 17 patients (85%) had intrahepatic recurrence within the follow-up period 
of which 12 were re-resected or re-ablated.  
In study III, MWA was performed during open surgery which has numerous advantages 
compared with a percutaneous approach. Antenna placement can be done from a wide range 
of angles and be further facilitated by liver mobilization. Concomitant liver resections can be 
performed and when ablating sub-capsular lesions, distancing of adjacent organs is easily 
done. Still, with reliable image-guidance technique, the laparoscopic approach is desirable 
and important for future development. Computer-assisted navigation, not requiring real-time 
visualization of lesions, was used in seven of the 20 patients in study III, demonstrating its 
feasibility. 
5.7 TARGETING ACCURACY IN STEREOTACTIC PERCUTANEOUS 
MICROWAVE ABLATION 
Antenna placement accuracy was slightly poorer in study IV related to other reports on the 
use of similar systems. Improved accuracy is to be expected as experience increases. An 
optical-based navigation system was utilized by Widmann et al. with a mean lateral error of 
3.6  2.5 mm (218) compared with 4.0  2.5 mm in study IV. Mbalisike used a robotic 
guidance system and compared it with manual guidance and achieved a significant 
improvement in applicator position with the robotic system (5.3 mm  1.8 mm and after 
manual readjustment; 1.9  1.7) (216). Another robotic system was used by Beyer et al., with 
improved accuracy compared with manual antenna insertion (3.1  2.5 mm and after manual 
correction; 1.6  1.3) (215). Notably, in both studies, manual correction was required to attain 
desired accuracy. Electromagnetically tracked antennae were used by Krücker which 
improved the tracking error to 2.7  1.6 mm (217). A low number of repositions of the 
antenna is desirable because of less need for repeated control scans, resulting in a reduced 
radiation exposure, and less insertion-related injuries. Longitudinal error is of minor 
importance in the clinical setting since further insertion or withdrawal of the antenna is easy 
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and does not require antenna replacement. The low antenna readjustment rate and seemingly 
larger target error of study IV perhaps reflect the study conductors’ acceptance of a larger 
error at the expense of an increased ablation zone. 
5.8 FEASIBILITY OF STEREOTACTIC MICROWAVE ABLATION 
Two minor complications occurred during study IV and no complications related to the use of 
HFJV. Technical error occurred during three procedures, omitting the use of the aiming 
device. Since the study included the first 20 patients on whom the system was used, technical 
failure is to be expected and did not happen at the expense of patient safety.  
The CT protocols for HCC and metastases were different since detection of HCC requires 
imaging during three contrast phases and hence was reported separately. For the group with 
metastases, the mean DLPinter was 264 ± 121 mGy × cm, whereas for the group with HCC, it 
was 502 ± 326 mGy × cm. This is in range with CT fluoroscopy-guided RFA/MWA of liver 
tumours used by Kloeckner et al., thus without computer or robotic guidance systems (253). 
Abdullah et al. used a CT-guided robotic positioning system, and demonstrated a 30% 
reduction in radiation dose per lesion, compared with the standard ablation procedure without 
the assistance of the robotic device. The difference was however not statistically significant 
(254). CT hardware, with expected annual updates, and protocols varies substantially 
between institutions, making a comparison of radiation dose between different studies 
unreliable and irrelevant. 
The procedural time, wide angular range of antenna insertion, different tumour location depth 
and tumour locations in all segments but segment one, all indicate the feasibility of the 
system used in study IV. 
Antenna placement accuracy is sometimes hampered by breathing-associated liver motion. 
Respiratory motion control in percutaneous ablation/biopsies is often achieved by 
disconnecting the airway tube from the ventilator at end expiration. Denys and colleagues 
used HFJV for percutaneous tumour ablation and measured a target movement of less than 
3.75 mm (slice thickness) (241). Conventional ventilation was compared with HFJV in 
percutaneous RFA of liver tumours and the latter was associated with a significant reduction 
in radiation (255). Biro et al. observed a 75% reduction in liver movement in a patient who 
underwent RFA of multiple liver tumours (256). Only the safety of HFJV was an endpoint in 
study IV, but its appealing characteristics warrant further evaluation in the clinical setting. 
5.9 METHODOLOGICAL CONSIDERATIONS AND LIMITATIONS 
5.9.1.1 Precision  
Assessing the accuracy of a study is done by evaluating its precision and validity. Precision 
mainly depends on sample size and random errors. It is most often expressed by confidence 
intervals; the wider the CI, the poorer the precision. Sample sizes of studies I and II are small 
and not based on power calculations. Study I was designed as a descriptive study and study II 
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aimed to evaluate the decision-making process where the time-consuming process of re-
evaluating imaging and patients in the setting of a fictive MDT was a limiting factor. There 
was also an ethical aspect of study II where we wished to minimize re-evaluation of any live 
study participants. Random errors occur in most studies and since they occur randomly, they 
do not tend to cause a false association. Random errors cannot be corrected for in a statistical 
analysis. 
5.9.1.2 Validity and systematic errors 
Validity is divided into external and internal validity where the former refers to its 
generalizability and whether the results of the study can be used in other populations and is 
dependent on the internal validity. The internal validity addresses the question “Does the 
study measure what it was intended to” and is dependent on different types of bias 
(systematic errors). Selection bias occurs when the selection of study participants is incorrect 
and non-representative. Information bias, also called misclassification, is subdivided into 
non-differential and differential misclassification. Differential misclassification is non-
random and can cause a false association. Non-differential misclassification, on the other 
hand, is random and usually dilutes the estimates toward the null (bias towards the null). 
Confounding is a factor associated with the outcome and exposure but not an intermediate 
link between exposure and outcome. Confounding can be adjusted for in numerous ways 
(randomization, restriction, stratifying, regression analyses etc.). Residual confounding is 
often present because of unknown confounders not adjusted for. 
Study I was a descriptive, population-based study based on the SCCR. The SCCR is a 
prospectively maintained database with confirmed high validity (5). Not all data required for 
studies I, II and III were available in the SCCR and acquiring all relevant data required a 
review of electronic patient records. When collecting the additional data, it is possible that 
information bias, most likely in the form of non-differential misclassification, was introduced 
in the data. This error could have been reduced by only using information from large 
validated registries. By only including patients from the greater Stockholm region, it might 
limit the external validity of studies I and II. Based on the results from Norén et al. (102, 
103), with Stockholm having a higher resection rate of liver metastases and not suffering 
from any gender discrimination in treatment of liver metastatic disease compared with the 
rest of Sweden, the generalizability of studies I and II could be questioned. 
A potential difference between midgut and hindgut cancer in study I was a hypothesis created 
“a posteriori”, hence the lack of variables interesting for that particular question such as 
mutation status. Since right-sided cancer is reported to be diagnosed at a later stage, adjusting 
for stage should have been done when assessing differences in right-sided versus left-sided 
cancer. Furthermore, various definitions exist in the literature in trials comparing right and 
left colon cancer on whether to include rectal tumours or not. In study I, rectal cancer was 
included and a comparison with previous literature might therefore be limited. Also, not 
adjusting for ASA grade in study I is a major limitation and most likely an important 
confounder. Adjusting for the administration of chemotherapy is complex. Major 
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improvements and changes in the indication for chemotherapy have occurred since 2008, this 
being the main reason why chemotherapy was not adjusted for. 
Expectation bias is when the researcher allows his or her expectations to affect the outcome 
of a study. This is of major importance in study II where the authors of the manuscript also 
constituted the fictive conference and were naturally not blinded to the hypothesis of the 
study. It is possible that the conference participants decided in favour of resection more often 
than would have been the case in an actual setting. Using Cohen’s kappa is thought to be a 
more accurate measure of interrater agreement than just percentage agreement calculation 
since  takes the possibility of the agreement occurring by chance into account. Kappa values 
over 0.75 are interpreted as excellent agreement. A way to further highlight any 
overestimation, and something that in retrospect could have been done, was to re-present 
randomly chosen cases at the fictive conference to see if the same fictive decisions were 
made. Study II lacked the power to detect any potential differences in referral rate. Another 
reservation about the study design of study II is the absence of specific competence within the 
fictive liver MDT, for example a thoracic surgeon, to decide on the resectability of 
pulmonary metastases. 
In study III it is possible that some of the patients included in the multiple ablation strategy 
group would have been considered as potentially resectable with more established 
combination methods in other institutions. Selection bias, as in selecting patients with 
potentially other favourable factors affecting survival, is almost always present in these kinds 
of studies. We have already passed the line where it is ethical to randomize unresectable 
patients into treatment with thermal ablation or not. Perhaps propensity score analysis is the 
best way to truly evaluate the benefit of thermal ablation. 
When analysing survival in study III, the numbers at risk after 36 months are low and should 
be interpreted with caution. Additionally, comparing cohorts from different time-periods, as 
is the case in study III and to some extent study II, always introduces bias since treatment 
algorithms, medication, surgical technique and indications continuously evolve. In study III, 
the palliative group treated with chemotherapy only, was selected solely based on imaging 
findings with tumour criteria corresponding to being treatable with MWA. It is likely that 
these patients had contraindications precluding resection and therefore constitute non-
comparable groups. 
As a feasibility study, study IV had restrictive inclusion and exclusion criteria and 
consequently an impaired external validity. Study IV does not provide any results on local 
tumour progression or any survival data. Navigation systems have obvious theoretical 
advantages over conventional US or CT guidance, but in order to establish their true impact 
on targeting accuracy and survival outcomes, comparative studies need to be done. An 
additional limitation in evaluating irradiation in study IV was the use of DLP rather than 
measured absorbed doses of the patients. 
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6 CONCLUSIONS 
 
Study I  
 Twenty-six percent of CRC patients develop liver metastases of which two thirds are 
synchronously detected. 
 Patients with liver metastatic midgut cancer had significantly worse OS compared to 
liver metastatic hindgut cancer. 
 Hindgut cancer had a higher incidence of liver metastases and lung metastases while 
midgut cancer had a higher incidence of peritoneal carcinomatosis. 
 The results from study I add to the ongoing research results showing clinical 
differences between right- and left-sided colon cancer. 
 OS was not influenced by the presence of lung metastases in patients with CRC. 
Study II 
 A meaningful number of patients with resectable/potentially resectable liver 
metastases were not evaluated in the setting of a liver MDT conference. 
 Referral rates to the liver MDT conference did not differ significantly between 
hospitals in the Stockholm region. 
Study III 
 In highly selected patients a multiple ablation strategy offers survival benefits 
compared to palliatively treated patients. 
 The majority of patients treated with multiple ablations suffer from both intra- and 
extrahepatic recurrence.  
Study IV 
 CT-guided stereotactic navigation for percutaneous MWA provides sufficient 









7 POPULÄRVETENSKAPLIG SAMMANFATTNING 
Tjock- och ändtarmscancer är den tredje vanligaste cancerformen i världen och Sverige. 
Varje år får cirka 4000 personer tjocktarmscancer i Sverige och motsvarande siffra för 
ändtarmscancer är 2000 personer. Tjocktarmscancer är lika vanligt hos män och kvinnor 
medan ändtarmscancer är något vanligare hos män. Tjock- och ändtarmscancer är framförallt 
en cancerform som drabbar den äldre befolkningen (över 65 år) och fem-årsöverlevnaden 
beräknas vara 61% för män och 65% för kvinnor. 
Sjukdomen kan sprida sig till andra organ, och vanligast är dottertumörer till levern vilket 
sker hos en dryg fjärdedel av alla patienter. Historiskt sett har prognosen för patienter med 
dottertumörer i levern varit dyster men tack vare utvecklingen av kirurgiska metoder och 
cellgifter så kan idag en fjärdedel opereras vilket resulterar i en 5-årsöverlevnad på upp till 
50%. Cellgifter kan förlänga livet hos en person med spridd cancer till levern men operation 
av dottertumörerna är det enda som är botande. Förutsättningen för att en operation ska kunna 
utföras är att det inte finns för många dottertumörer och att de inte är alltför spridda i levern.  
Omhändertagande av patienter med spridd cancer till levern ska ske inom ramen för en 
multidisciplinär terapikonferens där både leverkirurger, onkologer, radiologer och patologer 
deltar. Detta för att säkerställa att den mest optimala kombinationen av kirurgisk och 
onkologisk behandling erbjuds. Det har visat sig att om patienter med dottertumörer i levern 
bedöms av ett team med en leverkirurg så opereras fler och därmed så kan fler patienter 
botas. Tidigare studier har dock visat att långt ifrån alla patienter med dottertumörer i levern 
erbjuds operation och det finns stora skillnader mellan sjukhus i olika regioner när det gäller 
hur många som opereras för sina dottertumörer i levern.  
Mindre tumörer i levern, som av en eller annan anledning inte kan opereras bort, kan ibland 
förstöras med värme (radiofrekvensbehandling och mikrovågor). Den förmodat effektivaste 
tekniken är mikrovågor och innebär att en nålliknande antenn förs in i tumören och den 
värme som bildas omkring antennens spets förstör tumörvävnaden. Metoden kan bara 
användas på mindre tumörer och är inte bevisat lika effektiv som operation för dottertumörer. 
Levercancer är en cancerform som uppstår direkt i levern och för dessa tumörer är 
mikrovågor/radiovågor likvärdigt med operation. Utmaningen med värmebehandling är att 
lyckas föra in antennens spets till tumörens centrum. Detta görs med olika rikthjälpmedel; 
ultraljud, datortomografi eller GPS-liknande system. Alla tumörer är inte synliga med 
ultraljud och användandet av enbart datortomografi kan ge onödigt hög stråldos till både 
patient och sjukvårdspersonal.  
Denna avhandling består av fyra studier som alla berör olika aspekter av patienter med 
dottertumörer i levern; hur vanligt det är, hur överlevnaden ser ut, betydelsen av den 
multidisciplinära terapikonferensen och behandling med mikrovågor när operation inte går att 
utföra. Studie I syftade till att beskriva spridningsmönstret av dottertumörer hos patienter 
med tjock- och ändtarmscancer. Alla patienter som diagnostiserades med tjock- och 
ändtarmscancer i Stockholmsområdet under 2008 identifierades och följdes under 5 år. 
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Dottertumörer i levern påvisades hos 26.5% (272 patienter av 1026 med tjock- och 
ändtarmscancer). Spridning till lever och lungor var vanligare hos de med vänstersidig 
tjocktarmscancer och ändtarmscancer jämfört med de som hade högersidig tjocktarmscancer. 
Dock hade de med högersidig tjocktarmscancer fler dottertumörer i levern när de väl spridit 
sig dit och överlevnaden var betydligt sämre jämfört med patienter som hade vänstersidig 
cancer. Dessa resultat kan ha betydelse för hur patienter ska följas upp och belyser att det 
troligen finns molekylära och immunologiska skillnader mellan höger- och vänstersidig 
tjocktarmscancer. Spridning av dottertumörer till lungorna verkade inte påverka överlevnaden 
vilket är intressant eftersom patienter med dottertumörer i lungorna tidigare inte opererats då 
de ansetts ha en alltför spridd sjukdom. 
Syftet med studie II var att undersöka hur många som skulle kunna bli opererade för sina 
dottertumörer om alla bedömdes av en multidisciplinär terapikonferens med en leverkirurg 
närvarande. För att undersöka detta skapades en fiktiv konferens där alla patienter med 
dottertumörer i levern från studie I eftergranskades och ”nya” beslut fattades, oberoende av 
tidigare behandlingsbeslut. Från studie I hade vi sett att 102 (37.5%) patienter remitterades 
till leverkirurgisk terapikonferens men att resterande 170 patienter aldrig bedömdes av en 
leverkirurg. På den fiktiva konferensen bedömdes att ytterligare 22 patienter (12.9%) av de 
170 patienterna kunde ha opererats. Detta skulle innebära att under optimala förhållanden så 
borde närmare 40% av alla med dottertumörer i levern kunna opereras till skillnad från den 
faktiska siffran på cirka 25% från studie I. Denna studie betonar hur viktigt det är att alla 
med spridd tjock- och ändtarmscancer bedöms på en leverkirurgisk terapikonferens. 
I studie III inkluderades 20 patienter vars dottertumörer i levern inte gick att operera bort på 
grund av alltför omfattande spridning i levern. Syftet var att behandla dessa patienter med 
mikrovågor under öppen operation och utvärdera genomförbarheten och säkerheten med ett 
sådant tillvägagångssätt. Överlevnaden i studiegruppen jämfördes med de patienter från 
studie I som opererats och en grupp från studie I vars tumörer var jämförbara med de i 
studie III (till antal och storlek) men som i verkligheten enbart behandlades med cellgifter. 
Gruppen som värmebehandlades med mikrovågor hade mellan 4 och 22 dottertumörer och en 
fyra-årsöverlevnad på 41% att jämföra med 70% hos den historiska gruppen som opererades 
och 4% för de som enbart fick cellgifter. Dock hade arton av 20 patienter återfall av tumörer i 
levern och nio patienter drabbades av behandlingskrävande komplikationer relaterade till 
värmebehandlingen. Slutsatsen blir att det går att utföra värmebehandling med mikrovågor av 
många dottertumörer med vad som verkade vara en överlevnadsvinst jämfört med historiska 
material. Vidare studier med längre uppföljning och bättre jämförelsegrupper krävs dock för 
att utvärdera denna behandlingsstrategis plats hos patienter med många dottertumörer som 
inte går att operera bort. 
Bakgrunden till studie IV är att lokal värmebehandling har en hög återfallsfrekvens av 
tumörer vilket förmodligen beror på att storleken på området med tumördöd inte går att 
förutsäga tillräckligt exakt och att metoderna för att placera antennen centralt i tumören inte 
är precisa nog. För att öka precisionen har olika navigationssystem utvecklats. Tekniken 
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bygger på att bilder tagna i en datortomograf före operationen sammanfogas med en GPS-
liknande datorstyrd navigering varvid levertumörerna kan identifieras utan att man behöver 
öppna buken. Denna teknik hade innan start av studie IV visat sig fungera i modeller men 
var inte utvärderad på människor. Tekniken användes dock sedan tidigare vid öppen 
operation, det var bara kopplingen till röntgenbilderna som ännu inte var testad annat än i 
modeller.  
Syftet med studie IV var att utvärdera navigationssystemet för guidning av antennen vid 
värmebehandling med mikrovågor av tumörer i levern. Tjugo patienter med levercancer och 
dottertumörer från tjock- och ändtarmscancer inkluderades i studien. Tumörerna hos dessa 
patienter var inte synliga med ultraljud, det rikthjälpmedel som vanligast används när 
antennen ska placeras genom huden, och gick heller inte att operera bort. Antennens läge i 
relation till tumören, ingreppets stråldos, säkerhet och genomförbarhet utvärderades. 
Resultatet från studien var att antennen placerades i genomsnitt 5.8 mm från det tänka målet, 
viket är en acceptabel felmarginal. Stråldosen för varje patient var jämförbar med andra 
liknande studier och metoden hade en låg komplikationsfrekvens.  
Navigationssystemet används nu i klinisk vardag på Danderyds sjukhus för att placera 
mikrovågsantennen i tumörer när ultraljudsledning inte går att använda. Huruvida 
navigationssystemet ger en bättre precision än andra riktmedel (ultraljud och datortomografi), 
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8 FUTURE PERSPECTIVES 
Study I was mainly hypothesis generating and invites further studies on potential differences 
between midgut and hindgut cancers in metastatic disease and the pathogenesis behind it on a 
molecular level. This might influence and assist in more structured and individualized 
guidelines for follow-up routines. The impact of lung metastases on survival in CRC is 
another interesting subject, especially since the criteria for resectability are continuously 
expanding. Perhaps, unresectable lung metastases should not be considered an absolute 
contraindication for resection of liver or other extrahepatic metastases. The nature of 
population-based registries in Sweden could enable study designs that may answer some of 
these questions. 
Surgical techniques, chemotherapy options and perioperative care are continuously evolving 
and will result in further increased resection rates for CRCLM and hopefully improved 
survival. Ensuring that all potentially resectable patients are worked up with state-of-the art 
imaging and evaluated by a liver MDT should be key priorities. Referral of all patients with 
CRCLM may not be practical and affordable. If a selective referral policy is applied, it should 
be clear and to some point be regulated. It should be supported by education of 
gastroenterologists, medical oncologists and general and colorectal surgeons. 
A main focus for the liver research group at Danderyd Hospital is to further develop and 
validate the role of MWA in the treatment of CRCLM. Since the start of thermal ablation at 
Danderyd hospital, a prospective database with information on all patients and procedures has 
been maintained. This could serve as robust data to describe recurrence pattern, depending on 
tumour characteristics and interventional technique and access used. It will also be possible to 
generate long-term survival data. 
Microwave Ablation Versus Resection for Resectable Colorectal liver metastases 
(MAVERRIC) is an ongoing study aiming to prove that first line local ablation of CRCLM 
with MWA is not inferior to liver resections in a subset of patients in terms of survival rates, 
complication rates and need for further interventions. Patients that are resectable and have 
tumours of 30 mm or less and not more than five in number, and deemed as possible to ablate 
as well as resect, are offered treatment with an ablative strategy using state of the art 
navigation and MWA devices. The study cohort will be compared to controls from the 
Swedish liver registry using propensity score analysis.  
Estimating a correct ablation volume is crucial in reducing local recurrence rate and thermal 
induced injuries to adjacent structures and organs. The research group is planning to perform 
a study to quantify the post-ablation margins of patients that have undergone percutaneous 
navigated ablation of the liver to see which factors influence ablation volume to enable more 
accurate prediction of ablation volumes. Factors that could influence ablation volume, beside 
applied time and energy, include tumour type (hypervascular versus hypovascular tumours) 
and tissue elasticity or fibrosis, affected by underlying liver disease and chemotherapy. 
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Continuous development of the computer-assisted navigation system with software 
improvements and EM tracking of the antenna, both for percutaneous, laparoscopic and open 
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9 APPENDIX 
9.1 A. PATIENT INFORMATION AND CONSENT FORM FOR STUDY IV 
Valideringsstudie av datorstyrd navigering av ablationsnålar för 
behandling av levertumörer. 
Bakgrund och syfte: Detta är en vetenskaplig studie som syftat till att förbättra 
omhändertagandet av patienter med tumörer i levern som skall behandlas med 
mikrovågsablation.  
Idag används ultraljudsapparat för att under operationen kunna lokalisera tumörförändringar 
inne i levern, förändringar som ofta inte syns eller känns från leverytan. Det medför att 
behandlingen oftast måste göras under narkos på operation med en öppen buk och blottad 
leveryta. 
Det finns nu en ny teknik där man kan använda bilder tagna i datortomografi före operation, 
där man med hjälp av små plastkulor som tillfälligt limmas på huden nära levern, med en 
gps-liknande datorstyrd navigering kan hitta levertumörerna utan att behöva öppna buken. 
Denna teknik har visat sig fungera alldeles utmärkt i modeller men är inte utvärderad i 
kliniskt bruk. Däremot är navigeringsutrustningen och tekniken för att bränna levertumörer 
väl dokumenterad och i kliniskt bruk. Det är bara kopplingen till röntgenbilderna som ännu 
inte är testad annat än i modeller. 
Förfrågan om deltagande: Du är nu tillfrågad att vara med i denna studie för att se om 
denna teknik är bra och kan göra att man kan behandla levertumörer med mindre invasiv 
teknik, för att minska smärtor och förkorta vårdtider. Du tillfrågas eftersom du remitterats till 
Danderyds Sjukhus för mikrovågsbehandling av levertumörer. 
Hur går studien till? Behandlingen utförs i narkos. Innan operationen limmar man fast några 
små plastkulor på skinnet kring höger revbensbåge och därefter gör en ny datortomografi 
strax innan behandlingen som utförs i datortomografen på röntgen. Under behandlingen 
kommer dina tumörer att behandlas på samma sätt som vi annars gör, det vill säga med hjälp 
av mikrovågor, men i och med att du har hudmarkörer och en färsk 
datortomografiundersökning så kan vi utvärdera om det hade gått lika bra att göra med den 
nya tekniken, innan mikrovågsbehandlingen inleds säkerställs att nålen ligger mitt i tumören 
med hjälp av en riktad datortomografiundersökning. När operationen är klar är ditt deltagande 
i studien klar. 
Biobanksprover: Inga vävnadsprover tas tillvara för lagring i biobank. 
Vilka är riskerna? Denna forskningsstudie innebär två extra riktade 
datortomografiundersökningar med lägre stråldos än en vanlig datortomografiundersökning 
av levern. Denna stråldos motsvarar mindre än 30 års naturlig bakgrundsstrålning i 
Stockholm, vilket är en liten stråldos. 
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Finns det några fördelar? Deltagande i studien kan innebära fördelar då det med den nya 
tekniken i vissa fall går att behandla utan öppen operation med de risker ett stort buksnitt har. 
Dessutom görs behandlingen på alldeles färska röntgenbilder vilket i enstaka fall kan 
innebära att man hittar en ytterligare tumör som går att behandla samtidigt. 
Hantering av data och sekretess. Uppgifter om navigationsutrustningens precision 
avseende placering av mikrovågsnål i tumörerna kommer att sparas i en datoriserad 
forskningsdatabas tillsammans med uppgifter om tumörernas storlek och lokalisation, samt 
uppgifter om tidsåtgången för de olika momenten vid behandlingen. Personnummer kommer 
inte att ingå i databasen. Databearbetningen kommer delvis att genomföras tillsammans med 
den forskargrupp i Schweiz som tagit fram navigationsutrustningen. Dina svar och dina 
resultat kommer att behandlas så att inte obehöriga kan ta del av dem. Forskningsresultaten 
kommer sedan att presenteras i form av en vetenskaplig artikel där enskilda 
forskningspersoner inte går att identifiera. 
Hur får jag information om studiens resultat? Du får resultaten av din behandling innan 
hemskrivning från sjukhuset, oftast dagen efter behandlingen. Om du önskar kan du få en 
kopia av det slutgiltiga forskningsresultatet när studien är färdig. 
Försäkring, ersättning. Det normala försäkringsskyddet för behandlingar i sjukvården ingår, 
den så kallade patientskadeförsäkringen. Ekonomisk ersättning utgår inte annat än befrielse 
från patientavgiften. 
Frivillighet. Du har självklart rätt att när som helst utgå ur studien. Ditt deltagande i studien 
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